<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006415.pub3" GROUP_ID="MENSTR" ID="754605113003211118" MERGED_FROM="" MODIFIED="2017-01-15 21:55:28 +0000" MODIFIED_BY="Helen Nagels" REVIEW_NO="ZP673" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2017-01-15 21:55:27 +0000" MODIFIED_BY="Helen Nagels">
<TITLE>Surgery for tubal infertility</TITLE>
<CONTACT MODIFIED="2017-01-15 21:55:27 +0000" MODIFIED_BY="Helen Nagels"><PERSON ID="422DFBB182E26AA200991D56892EC1A4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ben Willem</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Mol</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor of Obstetrics and Gynecology</POSITION><EMAIL_1>ben.mol@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Discipline of Obstetrics and Gynaecology, School of Medicine, Robinson Research Institute</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Level 3, Medical School South Building</ADDRESS_1><ADDRESS_2>Frome Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>SA 5005</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 434122170</PHONE_1><PHONE_2>+61 8 8313 4099</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-01-15 21:55:27 +0000" MODIFIED_BY="Helen Nagels"><PERSON ID="z1508070422381969202979278059283" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Su Jen</FIRST_NAME><LAST_NAME>Chua</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>a1613284@student.adelaide.edu.au</EMAIL_1><ADDRESS><ORGANISATION>The University of Adelaide</ORGANISATION><CITY>Adelaide</CITY><ZIP>SA5005</ZIP><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="16915" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Valentine</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akande</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>valentine.akande@bristol.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>Directorate of Women's Health, Southmead Hospital</ORGANISATION><ADDRESS_1>Southmead Road</ADDRESS_1><CITY>Bristol</CITY><ZIP>BS10 5NB</ZIP><REGION>England</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 117 959 5171</PHONE_1><FAX_1>+44 117 959 5178</FAX_1></ADDRESS></PERSON><PERSON ID="422DFBB182E26AA200991D56892EC1A4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ben Willem</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Mol</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor of Obstetrics and Gynecology</POSITION><EMAIL_1>ben.mol@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Discipline of Obstetrics and Gynaecology, School of Medicine, Robinson Research Institute</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Level 3, Medical School South Building</ADDRESS_1><ADDRESS_2>Frome Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>SA 5005</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 434122170</PHONE_1><PHONE_2>+61 8 8313 4099</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-12-01 18:12:22 +1300" MODIFIED_BY="Helen E Nagels">
<UP_TO_DATE>
<DATE DAY="19" MONTH="10" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="10" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="10" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-01-16 10:40:22 +1300" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-01-16 10:21:29 +1300" MODIFIED_BY="Helen E Nagels">
<DATE DAY="16" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>The background and methods sections have been updated to current Cochrane standards.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-01-16 10:40:22 +1300" MODIFIED_BY="Helen E Nagels">
<DATE DAY="16" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>New searches did not identify any studies eligible for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-01-16 10:17:23 +1300" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-01-02 13:12:51 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-01-16 10:17:23 +1300" MODIFIED_BY="Helen E Nagels">
<DATE DAY="3" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-01-02 13:12:55 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendments made</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-01-03 01:04:00 +1300" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2017-01-03 01:04:00 +1300" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-01-03 01:04:00 +1300" MODIFIED_BY="[Empty name]">
<NAME>Robinson Research Institute, Adelaide</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-12-01 18:30:38 +1300" MODIFIED_BY="Helen E Nagels">
<SOURCE MODIFIED="2016-12-01 18:30:38 +1300" MODIFIED_BY="Helen E Nagels">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-01-16 10:48:01 +1300" MODIFIED_BY="Helen E Nagels">
<SUMMARY MODIFIED="2017-01-02 13:23:51 +1300" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-05-24 16:45:59 +1200" MODIFIED_BY="Helen E Nagels">Surgery versus IVF or expectant management for women with tubal infertility</TITLE>
<SUMMARY_BODY MODIFIED="2017-01-02 13:23:51 +1300" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Cochrane review authors investigated the effectiveness of fallopian tube surgery compared with in vitro fertilisation (IVF) or expectant management in overcoming infertility caused by tubal disease.</P>
<P>
<B>Background</B>
</P>
<P>Tubal surgery to overcome infertility caused by tubal disease is becoming popular, in part because of risks and costs related to IVF, which offers another option for overcoming tubal infertility. Benefits obtained from tubal surgery would potentially be sustained over multiple cycles and many years, even resulting in multiple livebirths. However, tubal surgery is expensive, as it requires additional specialist training and experience among gynaecologists who perform the procedure, and it can involve adverse effects (including ectopic pregnancies) and operative risks. The effectiveness of tubal surgery in comparison with no treatment (expectant management) or IVF in women with tubal infertility is unknown.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review identified no suitable trials. Our literature searches are current to October 2016.</P>
<P>
<B>Key results</B>
</P>
<P>No randomised evidence is currently available. Research is needed to obtain information about adverse outcomes and costs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-01-03 01:10:05 +1300" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-01-03 01:08:27 +1300" MODIFIED_BY="[Empty name]">
<P>Surgery remains an acceptable treatment modality for tubal infertility despite the rise in usage of in vitro fertilisation (IVF). Estimated livebirth rates after surgery range from 9% for women with severe tubal disease to 69% for those with mild disease; however, the effectiveness of surgery has not been rigorously evaluated in comparison with other treatments such as IVF and expectant management (no treatment). Livebirth rates have not been adequately assessed in relation to the severity of tubal damage. It is important to determine the effectiveness of surgery against other treatment options in women with tubal infertility because of concerns about adverse outcomes, intraoperative complications and costs associated with tubal surgery, as well as alternative treatments, mainly IVF.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-01-03 01:08:56 +1300" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to determine the effectiveness and safety of surgery compared with expectant management or IVF in improving the probability of livebirth in the context of tubal infertility (regardless of grade of severity).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-01-03 01:10:05 +1300" MODIFIED_BY="[Empty name]">
<P>We searched the following databases in October 2016: the Cochrane Gynaecology and Fertility (CGF) Group trials register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and PsycINFO; as well as clinical trials registries, sources of unpublished literature and reference lists of included trials and related systematic reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-01-02 13:16:26 +1300" MODIFIED_BY="[Empty name]">
<P>We considered only randomised controlled trials to be eligible for inclusion, with livebirth rate per participant as the primary outcome of interest.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-01-02 13:17:07 +1300" MODIFIED_BY="[Empty name]">
<P>We planned that two review authors would independently assess trial eligibility and risk of bias and would extract study data. The primary review outcome was cumulative livebirth rate. Pregnancy rate and adverse outcomes, including miscarriage rate, rate of ectopic pregnancy and rate of procedure-related complications, were secondary outcomes. We planned to combine data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). We planned to assess statistical heterogeneity using the I<SUP>2</SUP> statistic and to assess the overall quality of evidence for the main comparisons using GRADE methods<I>. </I>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-01-02 13:17:22 +1300" MODIFIED_BY="[Empty name]">
<P>We identified no suitable randomised controlled trials.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-01-02 13:18:51 +1300" MODIFIED_BY="[Empty name]">
<P>The effectiveness of tubal surgery relative to expectant management and IVF in terms of livebirth rates for women with tubal infertility remains unknown. Large trials with adequate power are warranted to establish the effectiveness of surgery in these women. Future trials should not only report livebirth rates per patient but should compare adverse effects and costs of treatment over a longer time. Factors that have a major effect on these outcomes, such as fertility treatment, female partner's age, duration of infertility and previous pregnancy history, should be considered. Researchers should report livebirth rates in relation to severity of tubal damage and different techniques used for tubal repair, including microsurgery and laparoscopic methods.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-01-16 10:48:01 +1300" MODIFIED_BY="Helen E Nagels">
<BACKGROUND MODIFIED="2017-01-05 16:30:36 +1300" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2017-01-03 01:13:48 +1300" MODIFIED_BY="[Empty name]">
<P>Tubal disease of the fallopian tubes is responsible for 25% to 35% of cases of female infertility (<LINK REF="REF-Serafini-1989" TYPE="REFERENCE">Serafini 1989</LINK>). Tubal disease can involve the proximal, distal or entire tube and varies in severity. Pelvic inflammatory disease is the most common cause of tubal disease, representing more than 50% of cases, and may affect the fallopian tube at multiple sites (<LINK REF="REF-Honore-1999" TYPE="REFERENCE">Honore 1999</LINK>). The Hull &amp; Rutherford classification (2002) is a simple classification system that separates infertile women into three categories according to severity of tubal damage, namely, mild/grade I, moderate/grade II and severe/grade III (<LINK REF="REF-Akande-2004" TYPE="REFERENCE">Akande 2004</LINK>). This system is defined in the section on inclusion criteria. Diagnosis is confirmed by hysterosalpingography (HSG) or laparoscopy.</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-01-03 01:18:21 +1300" MODIFIED_BY="[Empty name]">
<P>Treatment options include surgical tubal repair, expectant management (i.e. waiting/no specific intervention) and in vitro fertilisation (IVF). The effectiveness of these treatments has not been tested rigorously in the context of randomised controlled trials (RCTs).<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Surgery</HEADING>
<P>Despite operative risks (general anaesthetic, intraoperative and postoperative) and a high postoperative incidence of ectopic pregnancy, surgery for tubal infertility is considered an effective treatment option. Procedures such as salpingostomy (formation of an opening into a uterine tube for the purpose of drainage) or fimbrioplasty (breaking of scar tissue around the distal end of the tube) are widely performed for distal tubal obstruction. Surgery is considered a viable treatment option for women with mild tubal disease, and for severe disease, laparoscopic salpingectomy before IVF has a role in improving livebirth rates among women with hydrosalpinges (<LINK REF="REF-ASRM-2015" TYPE="REFERENCE">ASRM 2015</LINK>; <LINK REF="REF-Johnson-2010" TYPE="REFERENCE">Johnson 2010</LINK>; <LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>).</P>
<P>Tubal ectopic pregnancy - pregnancy in the fallopian tubes - is a potential adverse effect of tubal surgery. A large retrospective regional study from Denmark of 236 women who underwent tubal surgery or adhesiolysis (a procedure performed to remove scar tissue around the tube) reported an ectopic pregnancy rate of 16% (<LINK REF="REF-Mosgaard-1996" TYPE="REFERENCE">Mosgaard 1996</LINK>). Higher ectopic pregnancy rates have been associated with increasing severity of tubal damage (<LINK REF="REF-Akande-2004" TYPE="REFERENCE">Akande 2004</LINK>). Compared with the 2% incidence of ectopic pregnancy reported in the general population, rates of ectopic pregnancy after surgical correction of tubal abnormalities are reported to be 1% to 10% in mild tubal disease, up to 40% in severe pathology and 2.1% to 11% when IVF is performed in patients with tubal infertility (<LINK REF="REF-Schippert-2012" TYPE="REFERENCE">Schippert 2012</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Expectant management</HEADING>
<P>Pregnancies do occur without treatment in women with a diagnosis of tubal blockage (<LINK REF="REF-Collins-1983" TYPE="REFERENCE">Collins 1983</LINK>; <LINK REF="REF-Evers-1998" TYPE="REFERENCE">Evers 1998</LINK>; <LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>; <LINK REF="REF-Wiedemann-1996" TYPE="REFERENCE">Wiedemann 1996</LINK>). It has been suggested that this could be the result of beneficial effects of diagnostic tests required to establish infertility and the therapeutic value of counselling provided during outpatient visits (<LINK REF="REF-Collins-1983" TYPE="REFERENCE">Collins 1983</LINK>). In addition, chance inclusion of normal couples (i.e. those at the boundaries of normal reference ranges of fertility) with infertile couples during clinical studies may be contributory. It is likely that "post hoc ergo propter hoc" (i.e. the temporal association between event A and event B immediately implies causation of event B by event A) does not apply for some types of infertility, as the widely held assumption that infertile women serve as their own controls and hence any pregnancy after treatment can be attributed to said treatment may not hold true.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">IVF</HEADING>
<P>Tubal infertility remains a major indication for IVF, which completely bypasses tubal blockage and offers an 18% to 29% livebirth rate per cycle (<LINK REF="REF-AIHW-2012" TYPE="REFERENCE">AIHW 2012</LINK>; <LINK REF="REF-SART-2014" TYPE="REFERENCE">SART 2014</LINK>). As IVF involves manual fertilisation outside the normal reproductive system, it is expensive, invasive and not available to all infertile patients. IVF is associated with several potential complications, including multiple births and foetal anomalies (<LINK REF="REF-ASRM-2015" TYPE="REFERENCE">ASRM 2015</LINK>; <LINK REF="REF-El_x002d_Chaar-2009" TYPE="REFERENCE">El-Chaar 2009</LINK>). Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening adverse effect of ovulation induction. The intravascular depletion associated with OHSS can lead to dehydration, hypovolaemia (low volume of fluid in veins), electrolyte disturbances and thrombosis due to haemoconcentration. In IVF cycles, the rate of severe OHSS requiring hospitalisation is less than 0.01% (<LINK REF="REF-AIHW-2012" TYPE="REFERENCE">AIHW 2012</LINK>; <LINK REF="REF-HFEA-2015" TYPE="REFERENCE">HFEA 2015</LINK>). This figure increases with the number of oocytes retrieved at each cycle, reaching 4.0% when more than 20 oocytes have been retrieved (<LINK REF="REF-AIHW-2012" TYPE="REFERENCE">AIHW 2012</LINK>; <LINK REF="REF-HFEA-2015" TYPE="REFERENCE">HFEA 2015</LINK>). Older women have been shown to have poor success rates, and increased recognition of factors such as parity (number of children to whom a patient has given birth), duration of infertility, coexisting infertility factors and local IVF success rates can influence outcomes (<LINK REF="REF-AIHW-2012" TYPE="REFERENCE">AIHW 2012</LINK>; <LINK REF="REF-SART-2014" TYPE="REFERENCE">SART 2014</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2017-01-05 16:30:36 +1300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Surgery</HEADING>
<P>The largest case series to date reported an impressive intrauterine pregnancy rate of 72.8% (2369/3254) for terminal salpingo-neostomy and salpingo-ovariolysis performed in patients with tubo-peritoneal infertility (<LINK REF="REF-Ponomarev-2009" TYPE="REFERENCE">Ponomarev 2009</LINK>). However, the time period over which the pregnancy rate was measured was not mentioned in the study publication, which was provided in the form of a conference abstract. A recent meta-analysis combining 22 observational studies of women (N = 2810) undergoing salpingostomy for hydrosalpinges revealed a cumulative pregnancy rate of 20.0% (95% confidence interval (CI) 17.5% to 22.8%) at one year and 25.5% (95% CI 22.2% to 29.4%) at two years (<LINK REF="REF-Chu-2015" TYPE="REFERENCE">Chu 2015</LINK>). Although surgical techniques, participant characteristics and duration of follow-up were heterogeneous, study authors cited these as reasons for generalisability.</P>
<P>The second largest case series to date (N = 1669), which stratified participants according to severity of tubal disease, reported favourable pregnancy outcomes of 55% to 80% for those with mild tubal disease, including prior tubal ligation (n = 1517), and poor pregnancy outcomes of 10% for participants with severe disease (e.g. concurrent proximal and distal lesions, extended dense adhesions, sclerohypertrophic tube, intra-ampullary adhesions) (n = 152) at a minimum of two years of follow-up (<LINK REF="REF-Tran-2010" TYPE="REFERENCE">Tran 2010</LINK>). However, the significance of these positive results is limited by the risk of bias inherent to retrospective case series.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Expectant management</HEADING>
<P>A retrospective analysis of 109 women with proximal tubal occlusion reported a spontaneous pregnancy rate of 10% per patient and 1.6% per month (<LINK REF="REF-Wiedemann-1996" TYPE="REFERENCE">Wiedemann 1996</LINK>). This study showed that when assisted reproductive technology &#8211; in particular, gamete intrafallopian transfer (GIFT) &#8211; was used as a subsequent treatment, the pregnancy rate was increased to 50%. A retrospective cohort study of 562 couples with tubal factor infertility who were on the waiting list for IVF found that the 12-month cumulative spontaneous pregnancy rate was only 2.4% (95% CI 1.2% to 3.9%). More than 75% of these pregnancies occurred during the first three months on the waiting list (<LINK REF="REF-Evers-1998" TYPE="REFERENCE">Evers 1998</LINK>). Another study followed 1145 couples with infertility and noted that 61% (26/43) of conceptions among patients with infertility of tubal origin were treatment independent, defined as pregnancies that occur after no treatment, three months after medical management or 12 months after surgical management, respectively. Of note, a significant percentage of non-treated infertile couples also conceived - 35% (191/548). However, subgroup analysis revealed that pregnancies unrelated to treatment were less likely to occur in women with bilateral tubal occlusion (0%; 0/5) than in women with other less severe tubal lesions (68%; 26/38), further emphasising the need for comparative studies stratifying participants according to severity of disease (<LINK REF="REF-Collins-1983" TYPE="REFERENCE">Collins 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">IVF</HEADING>
<P>Analysis of cumulative data showed that women with tubal factor, both with and without other coexisting infertility factors, had a pregnancy rate in excess of 70% after four cycles of IVF and embryo transfer (<LINK REF="REF-Benadiva-1995" TYPE="REFERENCE">Benadiva 1995</LINK>). A meta-analysis of 14 retrospective studies compared pregnancy rates in women with tubal infertility with and without hydrosalpinx (accumulation of watery fluid in the tube as a consequence of distal obstruction) and revealed the pregnancy rate to be 31.2% for the 4588 women without hydrosalpinx who underwent IVF (<LINK REF="REF-Camus-1999" TYPE="REFERENCE">Camus 1999</LINK>). Most of the studies included in this meta-analysis did not specify the number of IVF cycles completed.<BR/>
</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2017-01-02 13:44:18 +1300" MODIFIED_BY="[Empty name]">
<P>Considerable uncertainty remains about whether surgical treatment is superior to expectant management and IVF in women with tubal factor infertility. Surgery is still commonly performed, especially in areas where reimbursement for IVF is not available. This systematic review evaluated the effectiveness and safety of surgery in comparison with other available treatments for women with tubal infertility.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-01-03 01:09:29 +1300" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to determine the effectiveness and safety of surgery compared with expectant management or IVF in improving the probability of livebirth in the context of tubal infertility (regardless of grade of severity).</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-01-16 10:40:51 +1300" MODIFIED_BY="Helen E Nagels">
<SELECTION_CRITERIA MODIFIED="2017-01-03 01:28:47 +1300" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-01-02 13:48:15 +1300" MODIFIED_BY="[Empty name]">
<P>We included published and unpublished randomised controlled trials (RCTs) comparing the clinical effectiveness of tubal surgery versus expectant management or IVF. We included cross-over trials if pre-cross-over data were available.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-01-03 01:27:38 +1300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Participants were required to meet all the criteria listed below.</P>
<OL>
<LI>Subfertile couples with infertility of at least one year&#8217;s duration.</LI>
<LI>Women younger than 40 years of age.</LI>
<LI>Women with minor/grade I, moderate/grade II or severe/grade III tubal damage confirmed before tubal surgery by hysterosalpingography (HSG) or laparoscopy.</LI>
<LI>Women who had undergone tubal surgery for minor/grade I, moderate/grade II or severe/grade III tubal damage after investigation.</LI>
</OL>
<P>According to the Hull &amp; Rutherford 2002 classification of tubal damage (<LINK REF="REF-Akande-2004" TYPE="REFERENCE">Akande 2004</LINK>), minor/grade I tubal damage is defined as:</P>
<OL>
<LI>tubal fibrosis absent even if tube occluded (proximally);</LI>
<LI>tubal distension absent even if tube occluded (distally);</LI>
<LI>mucosal appearances favourable; and</LI>
<LI>flimsy adhesions (peritubal-ovarian).</LI>
</OL>
<P>Moderate/grade II tubal damage is defined as:</P>
<OL>
<LI>unilateral severe tubal damage;</LI>
<LI>contralateral minor disease present or absent; and</LI>
<LI>'limited' dense adhesions of tubes and/or ovaries.</LI>
</OL>
<P>Severe/grade III tubal damage is defined as:</P>
<OL>
<LI>bilateral tubal damage;</LI>
<LI>extensive tubal fibrosis;</LI>
<LI>tubal distension greater than 1.5 cm;</LI>
<LI>abnormal mucosal appearance;</LI>
<LI>bipolar occlusion; and</LI>
<LI>'extensive' dense adhesions.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<OL>
<LI>Women 40 years of age or older.</LI>
<LI>Women with multiple or other causes of infertility such as ovulatory or sperm dysfunction.</LI>
<LI>Women who had undergone tubal sterilisation.</LI>
</OL>
<P>When trials included couples with infertility of various categories, we included only couples with tubal infertility. We excluded participants with other causes of infertility because their inclusion could have confounded outcomes. When we had doubt about the definitions of various grades of tubal infertility, we requested more information from study authors. If extraction of data is not possible for any reason, we will exclude that trial and will state the reason for exclusion. We will include in the review trials that cannot be included in the meta-analysis owing to insufficient data.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-01-03 01:28:47 +1300" MODIFIED_BY="[Empty name]">
<P>Included studies performed one or more comparisons of effectiveness of tubal surgery versus expectant management, or of tubal surgery versus IVF. We considered a variety of techniques for tubal surgery to be eligible, including microsurgery or macrosurgery, laparoscopy and minilaparotomy or laparotomy. No treatment for infertility was administered to couples undergoing expectant management. For women undergoing IVF, a standard IVF procedure was carried out according to standard protocols for controlled ovarian stimulation, oocyte retrieval under ultrasound guidance, insemination, embryo culture and transcervical replacement of embryos, most often between pro-nucleate and eight-cell stages. Embryo transfer up to the blastocyst stage and frozen replacement cycles were eligible for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-01-02 15:04:10 +1300" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-01-02 15:01:32 +1300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cumulative livebirth rate per couple, where cumulative refers to time-specific or cycle-specific rates over a given time or number of cycles, and livebirth is defined as the delivery of one or more living infants after 20 completed weeks of gestational age.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-01-02 15:04:10 +1300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cumulative pregnancy rate per participant/couple (evidence of a gestational sac, confirmed on ultrasonography, defines clinical pregnancy).</LI>
<LI>Pregnancy rate per participant/couple (evidence of clinical pregnancy - evidence of a gestational sac, confirmed on ultrasonography), including ectopic pregnancy, although multiple gestational sacs in one individual count as one clinical pregnancy).</LI>
<LI>Livebirth rate per cycle commenced.</LI>
<LI>Ectopic pregnancy rate per participant.</LI>
<LI>Multiple pregnancy rate per participant (demonstration of more than one sac with foetal pole on ultrasonographic scan defines multiple pregnancy).</LI>
<LI>Incidence of OHSS per participant.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-01-03 01:51:42 +1300" MODIFIED_BY="[Empty name]">
<P>We searched for all published and unpublished RCTs comparing tubal surgery versus expectant management or IVF, without language restriction, and in consultation with the Gynaecology and Fertility Group (CGF) Information Specialist.</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-01-03 01:51:11 +1300" MODIFIED_BY="[Empty name]">
<P>We searched the following databases.</P>
<OL>
<LI>Gynaecology and Fertility Group (CGFG) Specialised Register of Controlled Trials Procite (searched 19 October 2016) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>Central Register of Controlled Trials (CENTRAL) Ovid (searched 19 October 2016) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>MEDLINE Ovid (1946 to 19 October 2016) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
<LI>Embase Ovid (1974 to 19 October 2016) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
<LI>PsycINFO Ovid (1806 to 19 October 2016) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</LI>
<LI>Cumulative Index to Nursing and Allied Health Literature (CINAHL) EBSCO (1982 to 19 October 2016) (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</LI>
<LI>Database of Abstracts of Reviews of Effects (DARE) in the Cochrane Library (for reference lists from relevant non-Cochrane reviews) (searched 17 August 2015) (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</LI>
<LI>Trial registries for ongoing and registered trials.</LI>
<OL>
<LI>http://www.clinicaltrials.gov (a service of the US National Institutes of Health) (searched 24 November 2016) (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>).</LI>
<LI>http://www.who.int/trialsearch/Default.aspx (World Health Organization International Trials Registry Platform search portal) (searched 24 November 2016) (<LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>).</LI>
</OL>
<LI>Web of Science (searched 24 November 2016) (<LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>).</LI>
<LI>OpenGrey (unpublished literature from Europe) (searched 24 November 2016) (<LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>).</LI>
<LI>Latin American Caribbean Health Sciences Literature (LILACS, trials from the Portuguese and Spanish speaking world) (searched 24 November 2016) (<LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>).</LI>
<LI>PubMed and Google Scholar (for recent trials not yet indexed in MEDLINE) (searched 24 November 2016) (<LINK REF="APP-13" TYPE="APPENDIX">Appendix 13</LINK>; <LINK REF="APP-14" TYPE="APPENDIX">Appendix 14</LINK>).</LI>
<LI>ProQuest Dissertations &amp; Theses Global (searched 17 August to 24 November 2016) (<LINK REF="APP-15" TYPE="APPENDIX">Appendix 15</LINK>).</LI>
</OL>
<P>We combined the MEDLINE search with the Cochrane highly sensitive search strategy, which appears in the <I>Cochrane Handbook of Systematic Reviews of Interventions</I> (Version 5.0.2, Chapter 6, 6.4.11) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), to identify randomised trials. We combined the Embase, PsycINFO and CINAHL searches with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN).</P>
<P>We designed a new search strategy that differed from the strategy used in the previous version of this review, necessitating database searches covering inception up to October 2015. All searches were current to 19 October 2016.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-01-03 01:51:42 +1300" MODIFIED_BY="[Empty name]">
<P>We searched reference lists of articles retrieved by the search, along with conference abstracts not covered in the CGFG register, in liaison with the Information Specialist (<LINK REF="APP-16" TYPE="APPENDIX">Appendix 16</LINK>). We communicated with trial authors and experts in the field regarding additional trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-01-16 10:40:51 +1300" MODIFIED_BY="Helen E Nagels">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2017-01-02 15:12:26 +1300" MODIFIED_BY="[Empty name]">
<P>We planned that two review authors (SC and BM) would independently undertake selection of studies after an initial screen of titles and abstracts retrieved (by SC), employing the search strategy outlined above. We planned that study investigators would be contacted, as required, to clarify study eligibility. We resolved discrepancies by discussion. Review authors identified no RCTs via the search strategy. We documented the selection process on a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]">
<P>We planned that two review authors (SC and BM) would independently extract data from eligible studies and would resolve disagreements by discussion or by consultation with the third review author. Data extracted would include study characteristics and outcome data (see data extraction form for details; <LINK REF="APP-18" TYPE="APPENDIX">Appendix 18</LINK>). We would collate studies involving multiple publications in such a way that each study, with its unique study identifier and multiple references, rather than each report, would be considered a single unit of interest in the review.</P>
<P>We planned to extract the following data from studies selected for inclusion in the review.</P>
<OL>
<LI>Trial characteristics.</LI>
<LI>Characteristics of study participants.</LI>
<LI>Outcomes.</LI>
<LI>Analysis.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-01-03 01:53:02 +1300" MODIFIED_BY="[Empty name]">
<P>We planned that two review authors (SC and BM) would independently assess included studies for risk of bias using the Cochrane risk of bias assessment tool (www.cochrane-handbook.org) to assess selection (random sequence generation and allocation concealment), performance (blinding of participants and personnel), detection (blinding of outcome assessors), attrition (incomplete outcome data), reporting (selective reporting) and other bias. We planned to resolve disagreements by discussion with the third review author. We described all judgements fully and presented our conclusions in the risk of bias table.</P>
<P>We planned to search for within-trial selective reporting when obvious outcomes were not reported or were not reported in insufficient detail to allow inclusion and to seek published protocols for comparison with the final published study.<I>
<BR/>
</I>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-01-02 15:17:51 +1300" MODIFIED_BY="[Empty name]">
<P>For dichotomous data (e.g. livebirth rates), we planned to use numbers of events in the control and intervention groups of each study to calculate Peto odds ratios (ORs). We planned to present 95% confidence intervals for all outcomes. When data needed to calculate ORs were not available, we planned to utilise the most detailed numerical data available that might facilitate similar analyses of included studies (e.g. test statistics, P values). We planned to assess whether estimates calculated in the review for individual studies were compatible in each case with estimates reported in study publications.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-01-03 01:53:52 +1300" MODIFIED_BY="[Empty name]">
<P>We planned that the primary analysis would be randomised per woman, and we planned to include per pregnancy data for some outcomes (e.g. miscarriage). We would briefly summarise in an additional table data that did not allow valid analysis (e.g. "per cycle" data) and would not perform meta-analysis. We would count multiple livebirths (e.g. twins, triplets) as one livebirth event and would include only first-phase data obtained from cross-over trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-01-02 15:21:48 +1300" MODIFIED_BY="[Empty name]">
<P>We planned to analyse the data on an intention-to-treat basis as far as possible, and to attempt to obtain missing data from the original trialists. When these data could not be obtained, we planned to undertake imputation of individual values for the primary outcome only. We planned to assume that livebirths did not occur in participants without a reported outcome. For other outcomes, we planned to analyse only available data. We would perform sensitivity analysis of any imputation undertaken (see below).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-01-16 10:40:51 +1300" MODIFIED_BY="Helen E Nagels">
<P>We planned to consider whether clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a clinically meaningful summary. We would have assessed statistical heterogeneity by using the I<SUP>2</SUP> statistic (I<SUP>2 </SUP>greater than 50% would indicate substantial heterogeneity) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-01-03 01:54:54 +1300" MODIFIED_BY="[Empty name]">
<P>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, review authors planned to minimise their potential impact by ensuring a comprehensive search for eligible studies and by staying alert for duplication of data. If we included 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small study effects (the tendency for estimates of the intervention effect to be more beneficial in smaller studies).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-01-02 15:24:03 +1300" MODIFIED_BY="[Empty name]">
<P>If studies were sufficiently similar, we planned to combine the data using a fixed-effect model for the following comparisons.</P>
<OL>
<LI>Tubal surgery versus expectant management.</LI>
<LI>Tubal surgery versus IVF.</LI>
</OL>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-01-02 15:24:13 +1300" MODIFIED_BY="[Empty name]">
<P>We planned no subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]">
<P>We planned to conduct sensitivity analyses for the primary outcome to determine whether conclusions were robust to arbitrary decisions made regarding eligibility and analysis. These analyses were to include consideration of whether review conclusions would have differed if:</P>
<UL>
<LI>eligibility were restricted to studies without high risk of bias;</LI>
<LI>a random-effects model had been adopted;</LI>
<LI>alternative imputation strategies had been implemented; or</LI>
<LI>the summary effect measure was relative risk rather than odds ratio.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Overall quality of the body of evidence - 'Summary of findings' table</HEADING>
<P>We planned to prepare a 'Summary of findings' table using GRADEpro software (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>). This table would have evaluated the overall quality of the body of evidence for the main review outcomes (livebirth rate and pregnancy rate) according to GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). We would have justified judgements about evidence quality (high, moderate or low) and would have documented and incorporated these into reporting of results for each outcome. Two review authors (SC and BM) would have made judgements independently as needed.<I>
<BR/>
</I>
</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-01-03 01:57:26 +1300" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-01-03 01:57:26 +1300" MODIFIED_BY="[Empty name]">
<P>We identified no eligible trials for inclusion.</P>
<SEARCH_RESULTS MODIFIED="2017-01-02 15:28:23 +1300" MODIFIED_BY="[Empty name]">
<P>We included no RCTs.</P>
</SEARCH_RESULTS>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-01-03 01:57:26 +1300" MODIFIED_BY="[Empty name]">
<P>We found one related single-centre RCT that was performed at a university tertiary care centre in Iran from March 2002 to September 2004 (2.5-year period). This study included 13 participants with unilateral hydrosalpinx and recurrent abortion, detected on ultrasonography and hysterosalpingography, and thus did not meet our inclusion criteria, which required that couples would be subfertile.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We found no currently ongoing studies undertaken to compare the effectiveness of tubal surgery versus expectant management or IVF.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-01-02 15:30:49 +1300" MODIFIED_BY="[Empty name]">
<P>We identified no RCTs for inclusion in the review, so we could perform no assessment of methodological quality.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-01-02 15:31:23 +1300" MODIFIED_BY="[Empty name]">
<P>We found no RCTs that compared surgery versus expectant management or IVF in women with tubal infertility; therefore, we cannot report study data.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-01-16 10:48:01 +1300" MODIFIED_BY="Helen E Nagels">
<P>
<BR/>
</P>
<SUMMARY_OF_RESULTS MODIFIED="2017-01-02 15:32:28 +1300" MODIFIED_BY="[Empty name]">
<P>This review shows that evidence on this topic has not been provided by randomised controlled trials (RCTs).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-01-02 19:31:40 +1300" MODIFIED_BY="[Empty name]">
<P>No evidence was available. Despite potential risks of surgery, such as possibly increased risk of ectopic pregnancy, and despite widespread availability of in vitro fertilisation (IVF), surgical treatment remains a popular option. This is reflected by recent epidemiological data on fertility services indicating that although the ratio of IVF services to tubal surgery favours IVF, actual prevalence of tubal surgeries performed has remained static. In the United States, 3.2% of women 25 to 44 years of age with fertility problems have ever used reproductive surgery, and 3.1% have used IVF (<LINK REF="REF-Chandra-2014" TYPE="REFERENCE">Chandra 2014</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2017-01-02 15:37:42 +1300" MODIFIED_BY="[Empty name]">
<P>As this systematic review applied a newly designed search strategy that encompassed an extensive number of databases from conception, it is not likely that we missed relevant studies. However, we could not adequately assess publication bias by using a funnel plot owing to the scarcity of RCTs on this topic. We may have automatically excluded good quality observational studies that may adequately answer the study question owing to the nature of the protocol of this systematic review. Consideration must be given to incorporating such studies in future reviews because well-powered RCTs continue to be few.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-01-16 10:48:01 +1300" MODIFIED_BY="Helen E Nagels">
<P>As a result of the limited nature of available data, it has repeatedly been difficult to draw reliable conclusions on the effectiveness of surgery for tubal infertility. Until data from large RCTs with adequate power become available, clinical practice must be guided on the basis of available observational studies, many of which are confounded by bias due to the traditional method of using each couple as its own internal control, hence assuming that any fertility outcome could be totally attributed to the intervention performed. Moreover, very few observational studies have incorporated direct concurrent comparison of two or more cohorts undergoing different interventions, respectively.</P>
<P>A previous version of this review (<LINK REF="REF-Pandian-2008" TYPE="REFERENCE">Pandian 2008</LINK>) evaluated this topic, and a related review examined use of pelvic surgery for subfertility (<LINK REF="REF-Ahmad-2006" TYPE="REFERENCE">Ahmad 2006</LINK>). Neither these reviews nor any of the numerous non-Cochrane systematic reviews on this topic have produced solid answers over the past three decades. Reasons for the lack of well-designed RCTs in this area are manifold. The validity of the classification systems used to assess severity of tubal damage is questionable. Extent of tubal disease and the presence of pelvic pathology are important factors in the prognosis for success after surgical repair. The pregnancy outcome has been found to be uniformly poor after surgical treatment in patients with severe tubal disease (less than 15% pregnancy rate) (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-Akande-2004">Akande 2004</A>; <LINK REF="REF-Wu-1988" TYPE="REFERENCE">Wu 1988</LINK>). Selection of appropriate patients is an important determinant of outcomes after surgery and is not possible in the absence of a reliable classification system. The group of patients thought to be eligible for participation in such an RCT may, therefore, comprise a misrepresentation of the typical patient population required. Recruitment for such trials is impaired by the provision of insufficient patient information; an accepted, reliable method that can provide precise prognostic information for women with tubal damage is needed.<BR/>
<BR/>The advent of IVF has diminished the role of tubal surgery, and tubal infertility remains one of the major indications for IVF. Although it is expensive and invasive, IVF is the preferred choice for older women with severe tubal damage. With the reported livebirth rate per IVF cycle in most centres as high as 30% (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-SART-2014">SART 2014</A>), and in light of uncertainties surrounding the outcomes of tubal surgery, a preference for IVF may contribute to poor recruitment for surgical RCTs. Furthermore, women with tubal damage find the spontaneous pregnancy rate unacceptably low (12-month cumulative pregnancy rate (PR) of 2.4%); consequently, expectant management is an unattractive option for them (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-Evers-1998">Evers 1998</A>).</P>
<P>Funding constraints in some clinical situations mean that many women and clinicians continue to favour surgery. An additional advantage of surgery over IVF is the theoretically permanent restoration of the ability to naturally conceive for every ovulation cycle over a sustained period. This is compared with the high chance afforded by IVF over the few cycles performed and associated complications of multiple births, foetal anomalies and ovarian hyperstimulation syndrome (OHSS) (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-AIHW-2012">AIHW 2012</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-ASRM-2015">ASRM 2015</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-El_x002d_Chaar-2009">El-Chaar 2009</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1608302335227140606297103119543&amp;format=REVMAN#REF-HFEA-2015">HFEA 2015</A>). Tubal surgery may be the only treatment option for couples who object to IVF for religious, moral or emotional reasons. Finally, when effective, tubal surgery leads to sustainable improvement in fertility prospects, whereas IVF (apart from frozen embryos) provides only one chance.</P>
<P>Specific problems have been noted with RCTs that involve surgical procedures. It is difficult to standardise the surgical procedures being tested, as procedures evolve continuously and complications decrease as surgeons gain experience. The success rate of a specific procedure depends on the experience and skill of the surgeon. It is important that all participating surgeons undergo appropriate training before the start of an RCT to reach a certain minimal level of standardisation, but this is not always possible. Blinding of participants and surgeons in surgical trials is a potential source of bias, particularly as it is not always possible to do this when one of the interventions being tested is surgical. Financial support for surgical clinical trials is limited, and this is an ongoing problem.</P>
<P>Despite the problems described above, serious consideration should be given to conducting RCTs to determine the effectiveness of surgery in comparison with expectant management and IVF for tubal infertility. Inclusion of women with mild and moderate tubal disease and exclusion of women with severe tubal disease may provide a reasonable way forward.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-01-03 02:08:49 +1300" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-11-24 23:41:37 +1300" MODIFIED_BY="Su Jen Chua">
<P>The effectiveness of tubal surgery relative to expectant management and IVF in terms of livebirth rates for women with tubal infertility remains unknown.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-01-03 02:08:49 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised studies are needed to evaluate clinical outcomes and cost-effectiveness of tubal surgery compared with no treatment and IVF. Large RCTs with sufficient power are warranted. These trials should include a prolonged period of follow-up (possibly lasting several years). Treatment protocols, methods of sperm preparation (for IVF), numbers of embryos transferred (for IVF) and inclusion and exclusion criteria should be clearly stated. Participant characteristics should be clear (age, duration of infertility, infertility investigations and previous therapy). In addition, participants should be stratified according to severity of tubal lesions.</P>
<P>With regard to surgical interventions, researchers should describe the techniques used and the experience of the surgeon(s). Future trials should use adequate methods of randomisation and should clearly state numbers and reasons for drop-out and withdrawal. Allocation concealment should be adequate, and intention-to-treat analysis performed. Investigators should perform a power calculation and should provide a clear description of the improvement in treatment outcome that is considered clinically significant. Use of parallel rather than cross-over study design is also favourable for continued study of these events because the latter may exaggerate treatment effectiveness.<BR/>
<BR/>Outcome measures should include pregnancy rate (PR) and livebirth rate (LBR) per participant/couple. Although rates per cycle are commonly reported, they constitute a 'unit of analysis' error and do not generate valid estimates or confidence intervals. Estimation of cumulative LBRs is also important. So results can be expressed as cumulative LBR after 'n' cycles, researchers should provide results after each cycle separately. They should evaluate cumulative LBRs by means of Cox proportional hazard analysis, which is a form of survival analysis (<LINK REF="REF-Cohlen-2002" TYPE="REFERENCE">Cohlen 2002</LINK>). It is important that they include all cycles in the denominator. If cycles with poor outcomes are excluded, effectiveness can be exaggerated. In trials that include tubal surgery, researchers should state the number of ectopic pregnancies.<BR/>
<BR/>Trialists should report pregnancy outcomes in relation to different grades of tubal damage and must describe significant adverse outcomes such as ectopic pregnancy (this information is crucial).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-01-02 23:41:41 +1300" MODIFIED_BY="[Empty name]">
<P>Thanks to the Cochrane Gynaecology and Fertility Group for support provided.</P>
<P>The authors of the 2016 update acknowledge the contributions of Professor Bhattacharya, Dr Pandian and Dr Harrild to previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-01-16 10:05:14 +1300" MODIFIED_BY="Helen E Nagels">
<P>BM has received payment for consultancy from biopharmaceutical company ObsEva Geneva. SC and VA have no interests to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-01-02 23:44:14 +1300" MODIFIED_BY="[Empty name]">
<P>Su Jen Chua: literature search, data extraction, trial selection, quality assessment, data entry and analysis, writing of the first draft of the review.</P>
<P>Valentine Akande: development of the protocol, commenting on the draft of the review.</P>
<P>Ben Mol: trial selection, quality assessment, revising of the final draft of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-01-02 23:44:22 +1300" MODIFIED_BY="[Empty name]">
<P>For the 2016 update, we ensured that the definition of clinical pregnancy was consistent across review outcomes.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-01-15 21:55:28 +0000" MODIFIED_BY="Helen Nagels">
<STUDIES MODIFIED="2016-12-01 18:28:43 +1300" MODIFIED_BY="Helen E Nagels">
<INCLUDED_STUDIES MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua"/>
<EXCLUDED_STUDIES MODIFIED="2016-12-01 18:28:43 +1300" MODIFIED_BY="Helen E Nagels">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Zolghadri-2006" MODIFIED="2016-12-01 18:28:43 +1300" MODIFIED_BY="Helen E Nagels" NAME="Zolghadri 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-12-01 18:28:43 +1300" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zolghadri J, Momtahan M, Alborzi S, Mohammadinejad A, Khosravi D</AU>
<TI>Pregnancy outcome in patients with early recurrent abortion following laparoscopic tubal corneal interruption of a fallopian tube with hydrosalpinx</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>1</NO>
<PG>149-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4767137"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3024839"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-01-16 10:48:46 +1300" MODIFIED_BY="Helen E Nagels">
<ADDITIONAL_REFERENCES MODIFIED="2017-01-16 10:48:46 +1300" MODIFIED_BY="Helen E Nagels">
<REFERENCE ID="REF-Ahmad-2006" MODIFIED="2017-01-16 10:46:41 +1300" MODIFIED_BY="Helen E Nagels" NAME="Ahmad 2006" TYPE="COCHRANE_REVIEW">
<AU>Ahmad G, Watson A, Vandekerckhove P, Lilford R</AU>
<TI>Techniques for pelvic surgery in subfertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000221.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-AIHW-2012" MODIFIED="2017-01-02 23:49:21 +1300" MODIFIED_BY="[Empty name]" NAME="AIHW 2012" TYPE="BOOK">
<AU>Macaldowie A, Wang YA, Chambers GM, Sullivan EA</AU>
<SO>Assisted Reproductive Technology in Australia and New Zealand 2010</SO>
<YR>2012</YR>
<PB>AIHW</PB>
<CY>Canberra</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akande-2004" MODIFIED="2017-01-02 23:51:26 +1300" MODIFIED_BY="[Empty name]" NAME="Akande 2004" TYPE="JOURNAL_ARTICLE">
<AU>Akande VA, Cahill DJ, Wardle PG, Rutherford AJ, Jenkins JM</AU>
<TI>The predictive value of the 'Hull &amp; Rutherford' classification for tubal damage</TI>
<SO>British Journal of Obstetrics &amp; Gynaecology</SO>
<YR>2004</YR>
<VL>111</VL>
<PG>123-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ASRM-2015" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NAME="ASRM 2015" TYPE="JOURNAL_ARTICLE">
<AU>Practice Committee of the American Society for Reproductive Medicine</AU>
<TI>Role of tubal surgery in the era of assisted reproductive technology: a committee opinion</TI>
<SO>Fertility and Sterility</SO>
<YR>2015</YR>
<VL>103</VL>
<PG>e37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benadiva-1995" MODIFIED="2017-01-02 23:50:47 +1300" MODIFIED_BY="[Empty name]" NAME="Benadiva 1995" TYPE="JOURNAL_ARTICLE">
<AU>Benadiva CA, Kligman I, Davis O, Rozenwaks Z</AU>
<TI>In vitro fertilisation versus tubal surgery: is pelvic reconstructive surgery obsolete?</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<PG>1051-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Camus-1999" MODIFIED="2008-04-21 15:11:04 +1200" MODIFIED_BY="jane clarke" NAME="Camus 1999" TYPE="JOURNAL_ARTICLE">
<AU>Camus E, Poncelet C, Goffinet F, Wainer B, Merlet F, Nisand I et al</AU>
<TI>Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies</TI>
<SO>Human Reproduction</SO>
<YR>1999</YR>
<VL>14(5)</VL>
<PG>1243-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chandra-2014" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NAME="Chandra 2014" TYPE="JOURNAL_ARTICLE">
<AU>Chandra A, Copen CE, Stephen EH</AU>
<TI>Infertility service use in the United States: data from the National Survey of Family Growth, 1982-2010</TI>
<SO>National Health Statistics Report</SO>
<YR>2014</YR>
<VL>73</VL>
<PG>1-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chu-2015" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NAME="Chu 2015" TYPE="JOURNAL_ARTICLE">
<AU>Chu J, Harb HM, Gallos ID, Dhillon R, Al-Rshoud FM, Robinson L et al</AU>
<TI>Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis</TI>
<SO>Human Reproduction</SO>
<YR>2015</YR>
<VL>30</VL>
<PG>1882-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohlen-2002" MODIFIED="2008-04-21 15:30:22 +1200" MODIFIED_BY="jane clarke" NAME="Cohlen 2002" TYPE="COCHRANE_REVIEW">
<AU>Cohlen BJ, Hughes E, te Velde ER</AU>
<TI>Intra-uterine insemination for unexplained subfertility (Protocol for a Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-04-21 15:30:22 +1200" MODIFIED_BY="jane clarke"><IDENTIFIER MODIFIED="2008-04-21 15:30:22 +1200" MODIFIED_BY="jane clarke" TYPE="DOI" VALUE="10.1002/14651858.CD003854"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-1983" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NAME="Collins 1983" TYPE="JOURNAL_ARTICLE">
<AU>Collins JA, Wrixon W, Janes LB, Wilson EH</AU>
<TI>Treatment-independent pregnancy among infertile couples</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Chaar-2009" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NAME="El-Chaar 2009" TYPE="JOURNAL_ARTICLE">
<AU>El-Chaar D, Yang Q, Gao J, Bottomley J, Leader A, Wen SW et al</AU>
<TI>Risk of birth defects increased in pregnancies conceived by assisted human reproduction</TI>
<SO>Fertility and Sterility</SO>
<YR>2009</YR>
<VL>92</VL>
<PG>1557-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evers-1998" NAME="Evers 1998" TYPE="JOURNAL_ARTICLE">
<AU>Evers JLH, de Haas HW, Land JA, Dumoulin JCM, Dunselman GAJ</AU>
<TI>Treatment-independent pregnancy rate in patients with severe reproductive disorders</TI>
<SO>Human Reproduction</SO>
<YR>1998</YR>
<VL>13(5)</VL>
<PG>1206-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2016-12-01 18:24:08 +1300" MODIFIED_BY="Helen E Nagels" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>accessed 27 January 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harzing-2007" MODIFIED="2017-01-02 23:55:36 +1300" MODIFIED_BY="[Empty name]" NAME="Harzing 2007" TYPE="OTHER">
<AU>Harzing, A-W</AU>
<TI>Publish or perish</TI>
<SO>Research in international management. http://www.harzing.com/pop.htm. 2007</SO>
<YR>(accessed 24 November 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HFEA-2015" MODIFIED="2017-01-05 15:49:39 +1300" MODIFIED_BY="Su Jen Chua" NAME="HFEA 2015" TYPE="OTHER">
<AU>Human Fertilisation and Embryology Authority</AU>
<TI>Adverse incidents in fertility clinics: lessons to learn</TI>
<SO>www.HFEA.gov.uk. (accessed 11th July 2016)</SO>
<YR>September 2015</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2017-01-03 00:05:44 +1300" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins J, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2005</YR>
<EN>Version 4.2.5. May 2005</EN>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-01-03 00:06:24 +1300" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<EN>Version 5.1.0. March 2011</EN>
<PB>The Cochrane Collaboration</PB>
<CY>London, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honore-1999" MODIFIED="2017-01-03 00:06:49 +1300" MODIFIED_BY="[Empty name]" NAME="Honore 1999" TYPE="JOURNAL_ARTICLE">
<AU>Honore GM, Holden AE, Schenken RS</AU>
<TI>Pathophysiology and management of proximal tubal blockage</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>71</VL>
<PG>785-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2010" MODIFIED="2017-01-05 16:35:31 +1300" MODIFIED_BY="[Empty name]" NAME="Johnson 2010" TYPE="COCHRANE_REVIEW">
<AU>Johnson N, van Voorst S, Sowter MC, Strandell A, Mol BW</AU>
<TI>Surgical treatment for tubal disease in women due to undergo in vitro fertilisation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-01-05 16:35:31 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-01-05 16:35:31 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002125.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mosgaard-1996" MODIFIED="2017-01-03 00:07:32 +1300" MODIFIED_BY="[Empty name]" NAME="Mosgaard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mosgaard B, Hertz J, Steenstrup BR, Soorensen SS, Lindhard A, Anderson AN</AU>
<TI>Surgical management of tubal infertility: a regional study</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1996</YR>
<VL>75(5)</VL>
<PG>469-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2004" MODIFIED="2017-01-03 00:08:58 +1300" MODIFIED_BY="[Empty name]" NAME="NICE 2004" TYPE="OTHER">
<AU>National Collaborating Centre for Women's and Children's Health</AU>
<TI>Fertility: Assessment and Treatment for People With Fertility Problems</TI>
<SO>Clinical Guideline. London: RCOG Press,</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ponomarev-2009" MODIFIED="2017-01-03 00:09:35 +1300" MODIFIED_BY="[Empty name]" NAME="Ponomarev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ponomarev VV, Zhuyko AA, Artyushkov VV, Bashirov EV, Vengerenko ME</AU>
<TI>Our experience in laparoscopic treatment of tubo-peritoneal infertility</TI>
<SO>Gynecological Surgery</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>S149-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SART-2014" MODIFIED="2017-01-03 00:10:50 +1300" MODIFIED_BY="[Empty name]" NAME="SART 2014" TYPE="BOOK">
<AU>Centers for Disease Control and Prevention/American Society for Reproductive Medicine/Society for Assisted Reproductive Technology</AU>
<SO>2012 Assisted Reproductive Technology National Summary Report</SO>
<YR>2014</YR>
<PB>US Department of Health and Human Services</PB>
<CY>Atlanta, GA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schippert-2012" MODIFIED="2017-01-03 00:11:19 +1300" MODIFIED_BY="[Empty name]" NAME="Schippert 2012" TYPE="JOURNAL_ARTICLE">
<AU>Schippert C, Soergel P, Staboulidou I, Bassler C, Gagalick S, Hillemanns P et al</AU>
<TI>The risk of ectopic pregnancy following tubal reconstructive microsurgery and assisted reproductive technology procedures</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>2012</YR>
<VL>285</VL>
<PG>863-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serafini-1989" NAME="Serafini 1989" TYPE="JOURNAL_ARTICLE">
<AU>Serafini P, Batzofin J</AU>
<TI>Diagnosis of female infertility</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1989</YR>
<VL>34</VL>
<PG>29-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tran-2010" MODIFIED="2017-01-03 00:11:40 +1300" MODIFIED_BY="[Empty name]" NAME="Tran 2010" TYPE="JOURNAL_ARTICLE">
<AU>Tran DK</AU>
<TI>Can open tubal microsurgery still be helpful in tubal infertility treatment?</TI>
<SO>Gynecological Surgery</SO>
<YR>2010</YR>
<VL>7</VL>
<PG>385-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiedemann-1996" NAME="Wiedemann 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wiedemann R, Sterzik K, Gombisch V, Stuckensen J, Montag M</AU>
<TI>Beyond recanalizing proximal tubal occlusion: the argument for further diagnosis and classification</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11(5)</VL>
<PG>986-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-1988" MODIFIED="2017-01-03 00:12:11 +1300" MODIFIED_BY="[Empty name]" NAME="Wu 1988" TYPE="JOURNAL_ARTICLE">
<AU>Wu CH, Gocial B</AU>
<TI>A pelvic scoring system for infertility surgery</TI>
<SO>International Journal of Fertility</SO>
<YR>1988</YR>
<VL>33</VL>
<PG>341-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-01-16 10:46:47 +1300" MODIFIED_BY="Helen E Nagels">
<REFERENCE ID="REF-Pandian-2008" MODIFIED="2017-01-05 16:39:32 +1300" MODIFIED_BY="[Empty name]" NAME="Pandian 2008" TYPE="COCHRANE_REVIEW">
<AU>Pandian Z, Akande VA, Harrild K, Bhattacharya S</AU>
<TI>Surgery for tubal infertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2017-01-05 16:39:32 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-01-05 16:39:32 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006415.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-01-02 23:48:06 +1300" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-01-02 23:48:06 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-11-24 23:42:06 +1300" MODIFIED_BY="Su Jen Chua" STUDY_ID="STD-Zolghadri-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-24 23:42:06 +1300" MODIFIED_BY="Su Jen Chua">
<P>Did not satisfy inclusion criteria. Participants were not subfertile.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-05-21 19:59:07 +1200" MODIFIED_BY="Su Jen Chua" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-12-01 18:15:40 +1300" MODIFIED_BY="Helen E Nagels" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-10-15 23:20:28 +1300" MODIFIED_BY="Su Jen Chua" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-10-15 23:21:00 +1300" MODIFIED_BY="Su Jen Chua"/>
<ADDITIONAL_TABLES MODIFIED="2015-10-01 02:06:41 +1300" MODIFIED_BY="Su Jen Chua"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-10-15 23:21:18 +1300" MODIFIED_BY="Su Jen Chua"/>
<FIGURES MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcYAAAMACAYAAAC+TMepAABma0lEQVR42u2dD4RVz///vyRJkkje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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-01-03 01:04:54 +1300" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-01-03 01:04:54 +1300" MODIFIED_BY="[Empty name]">Gynaecology and Fertility Group Specialised Register</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 15:38:11 +1300" MODIFIED_BY="[Empty name]">
<P>(searched from inception to 19 October 2016) (PROCITE platform)</P>
<P>Keywords CONTAINS "Fallopian tube obstruction" or "tubal factor" or "tubal flushing" or "tubal infertility" or "tubal inflation" or "tubal occlusion" or "tubal occlusion - proximal" or "tubal patency" or "tubal reconstruction" or "tubal subfertility" or "tube drainage" or "tuboplasty" or "Fallopian Tube Fixation" or "fallopian tubes" or "tubal anastomosis" or "tubal disorders" or "tubo-ovarian abscess" or "salpingectomy" or "Salpingitis-Physiopathology" or "salpingo-oopherectomy" or "Salpingolysis" or "*Salpingostomy-"or "salpingotomy" or "Hydrosalpinx" or "hydrosalpingies" or "hydrosalpinges" or "falloscopy" or "laparoscopic salpingectomy" or "laparoscopic salpingoovolysis" or "laparoscopic salpingotomy" or "laparoscopic tubal fulguration" or "microsurgery" or "microscopic" or "microdiathermy" or "microlaparoscopy" or "hydrotubation" (446 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-10-19 15:49:12 +1300" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-10-19 15:49:12 +1300" MODIFIED_BY="[Empty name]">CENTRAL CRSO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 15:48:59 +1300" MODIFIED_BY="[Empty name]">
<P>(searched from inception to 19 October 2016) (CRSO web platform)</P>
<P>#1 MESH DESCRIPTOR Fallopian Tube Diseases EXPLODE ALL TREES 137</P>
<P>#2 MESH DESCRIPTOR Pelvic Inflammatory Disease EXPLODE ALL TREES 422</P>
<P>#3 MESH DESCRIPTOR Salpingitis EXPLODE ALL TREES 42</P>
<P>#4 (tubal infertility):TI,AB,KY 52</P>
<P>#5 ( tubal factor):TI,AB,KY 55</P>
<P>#6 (disten* adj3 tub*):TI,AB,KY 5</P>
<P>#7 (tubal subfertility):TI,AB,KY 2</P>
<P>#8 (tub* adj3 occlusion*):TI,AB,KY 163</P>
<P>#9 (tube* adj3 damage*):TI,AB,KY 7</P>
<P>#10 (tubal adj3 damage*):TI,AB,KY 12</P>
<P>#11 (adhesion* adj3 tub*):TI,AB,KY 22</P>
<P>#12 fallopian:TI,AB,KY 534</P>
<P>#13 (peritubal adj3 adhesion*):TI,AB,KY 3</P>
<P>#14 (tub* adj3 block*):TI,AB,KY 78</P>
<P>#15 hydrosalpin*:TI,AB,KY 53</P>
<P>#16 (Tub* adj3 lesion*):TI,AB,KY 46</P>
<P>#17 (disease* adj3 tub*):TI,AB,KY 222</P>
<P>#18 (occlu* adj3 oviduct*):TI,AB,KY 2</P>
<P>#19 (adhesion* adj3 oviduct*):TI,AB,KY 2</P>
<P>#20 (Tub* adj3 obstruction*):TI,AB,KY 61</P>
<P>#21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 1531</P>
<P>#22 MESH DESCRIPTOR Gynecologic Surgical Procedures EXPLODE ALL TREES 3630</P>
<P>#23 MESH DESCRIPTOR Salpingectomy EXPLODE ALL TREES 22</P>
<P>#24 MESH DESCRIPTOR salpingostomy EXPLODE ALL TREES 38</P>
<P>#25 MESH DESCRIPTOR Hand-Assisted Laparoscopy EXPLODE ALL TREES 7</P>
<P>#26 MESH DESCRIPTOR Laparoscopy EXPLODE ALL TREES 4243</P>
<P>#27 Laparoscop*:TI,AB,KY 9365</P>
<P>#28 MESH DESCRIPTOR Laparotomy EXPLODE ALL TREES 622</P>
<P>#29 Laparotomy:TI,AB,KY 1812</P>
<P>#30 electrosurg*:TI,AB,KY 352</P>
<P>#31 MESH DESCRIPTOR Electrosurgery EXPLODE ALL TREES 204</P>
<P>#32 MESH DESCRIPTOR Microsurgery EXPLODE ALL TREES 518</P>
<P>#33 microsurg*:TI,AB,KY 732</P>
<P>#34 minilaparotom*:TI,AB,KY 106</P>
<P>#35 (tubo-cornual anastomosis):TI,AB,KY 0</P>
<P>#36 fimbrioplasty:TI,AB,KY 6</P>
<P>#37 adhesiolysis:TI,AB,KY 85</P>
<P>#38 reconstruction:TI,AB,KY 3866</P>
<P>#39 (recanalizing or recanalising):TI,AB,KY 7</P>
<P>#40 (recanalisation or recanalization):TI,AB,KY 872</P>
<P>#41 (salpingostomy or salpingectomy):TI,AB,KY 142</P>
<P>#42 aspiration:TI,AB,KY 3801</P>
<P>#43 electrocoagulation:TI,AB,KY 716</P>
<P>#44 MESH DESCRIPTOR Sclerotherapy EXPLODE ALL TREES 432</P>
<P>#45 Sclerotherap*:TI,AB,KY 1153</P>
<P>#46 emboli?ation:TI,AB,KY 1111</P>
<P>#47 excision*:TI,AB,KY 3333</P>
<P>#48 #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 27783</P>
<P>#49 #21 AND #48 358</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-10-19 15:49:31 +1300" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-08-18 13:38:40 +1200" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 15:49:31 +1300" MODIFIED_BY="[Empty name]">
<P>(searched form 1946 to 19 October 2016) (Ovid platform)</P>
<P>1 exp fallopian tube diseases/ or pelvic inflammatory disease/ or salpingitis/ (11952)<BR/>2 tubal infertility.tw. (707)<BR/>3 tubal subfertility.tw. (14)<BR/>4 tubal factor.tw. (719)<BR/>5 tubal fibrosis.tw. (6)<BR/>6 (disten$ adj3 tube).tw. (70)<BR/>7 (disten$ adj3 tubal).tw. (10)<BR/>8 tubal occlusion.tw. (912)<BR/>9 (occlusion adj3 tubes).tw. (70)<BR/>10 (occlusion adj3 tube).tw. (306)<BR/>11 ((tube adj3 damage) or (tubal adj3 damage)).tw. (426)<BR/>12 (tube adj3 damage).tw. (124)<BR/>13 (adhesion$ adj3 tubal).tw. (199)<BR/>14 (adhesion$ adj3 tube).tw. (216)<BR/>15 (adhesion$ adj3 tubes).tw. (66)<BR/>16 fallopian.tw. (9086)<BR/>17 (peritubal adj3 adhesion$).tw. (117)<BR/>18 (tube adj3 block$).tw. (530)<BR/>19 (tubal adj3 block$).tw. (160)<BR/>20 (tubes adj3 block$).tw. (206)<BR/>21 hydrosalpin$.tw. (842)<BR/>22 ((Tubal adj3 lesion$) or (Tube adj3 lesion$)).tw. (240)<BR/>23 ((disease$ adj3 tubal) or (disease$ adj3 tubes)).tw. (576)<BR/>24 (oviduct$ adj3 damage$).tw. (33)<BR/>25 (oviduct$ adj3 fibrosis).tw. (4)<BR/>26 (disten$ adj3 oviduct$).tw. (7)<BR/>27 (occlu$ adj3 oviduct$).tw. (48)<BR/>28 (adhesion$ adj3 oviduct$).tw. (24)<BR/>29 ((Tubal adj3 obstruction$) or (Tube adj3 obstruction$)).tw. (1058)<BR/>30 1 and 29 (266)<BR/>31 or/1-28,30 (21711)<BR/>32 gynecologic surgical procedures/ or salpingectomy/ or salpingostomy/ (9590)<BR/>33 (surgery or surgical).tw. (1441006)<BR/>34 32 and 33 (6300)<BR/>35 laparoscopy/ or hand-assisted laparoscopy/ (70173)<BR/>36 Laparoscop$.tw. (101252)<BR/>37 Laparotomy/ (17222)<BR/>38 Laparotomy.tw. (40722)<BR/>39 electrosurgery/ or microsurgery/ (28971)<BR/>40 microsurg$.tw. (22043)<BR/>41 minilaparotom$.tw. (994)<BR/>42 tubo-cornual anastomosis.tw. (1)<BR/>43 fimbrioplasty.tw. (71)<BR/>44 adhesiolysis.tw. (1226)<BR/>45 reconstruction.tw. (160461)<BR/>46 (recanalizing or recanalising).tw. (173)<BR/>47 (recanalisation or recanalization).tw. (9700)<BR/>48 (salpingostomy or salpingectomy).tw. (1786)<BR/>49 aspiration.tw. (68032)<BR/>50 electrocoagulation.tw. (2763)<BR/>51 Sclerotherapy/ (4766)<BR/>52 Sclerotherap$.tw. (6126)<BR/>53 emboli?ation.tw. (39239)<BR/>54 or/32,34-53 (469023)<BR/>55 31 and 54 (5028)<BR/>56 randomized controlled trial.pt. (432907)<BR/>57 controlled clinical trial.pt. (91818)<BR/>58 randomized.ab. (373391)<BR/>59 randomised.ab. (76600)<BR/>60 placebo.tw. (185046)<BR/>61 clinical trials as topic.sh. (180215)<BR/>62 randomly.ab. (265326)<BR/>63 trial.ti. (163366)<BR/>64 (crossover or cross-over or cross over).tw. (71526)<BR/>65 or/56-64 (1126803)<BR/>66 exp animals/ not humans.sh. (4325953)<BR/>67 65 not 66 (1039022)<BR/>68 55 and 67 (282)<BR/>
</P>
<P>Utilising the Cochrane Highly Sensitive Search Strategies for identifying randomised trials in MEDLINE (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2017-01-03 01:05:16 +1300" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-05 16:31:54 +1300" MODIFIED_BY="[Empty name]">
<P>(searched from 1974 to 19 October 2016) (Ovid platform)</P>
<P>1 exp uterine tube disease/ or pelvic inflammatory disease/ or salpingitis/ (14863)<BR/>2 tubal infertility.tw. (828)<BR/>3 tubal subfertility.tw. (15)<BR/>4 tubal factor.tw. (875)<BR/>5 tubal fibrosis.tw. (6)<BR/>6 (disten$ adj3 tube).tw. (84)<BR/>7 (disten$ adj3 tubal).tw. (17)<BR/>8 tubal occlusion.tw. (949)<BR/>9 (occlusion adj3 tubes).tw. (64)<BR/>10 (occlusion adj3 tube).tw. (332)<BR/>11 ((tube adj3 damage) or (tubal adj3 damage)).tw. (476)<BR/>12 (tube adj3 damage).tw. (133)<BR/>13 (adhesion$ adj3 tubal).tw. (251)<BR/>14 (adhesion$ adj3 tube).tw. (222)<BR/>15 (adhesion$ adj3 tubes).tw. (62)<BR/>16 fallopian.tw. (9749)<BR/>17 (peritubal adj3 adhesion$).tw. (140)<BR/>18 (tube adj3 block$).tw. (617)<BR/>19 (tubal adj3 block$).tw. (221)<BR/>20 (tubes adj3 block$).tw. (242)<BR/>21 hydrosalpin$.tw. (1071)<BR/>22 ((Tubal adj3 lesion$) or (Tube adj3 lesion$)).tw. (309)<BR/>23 ((disease$ adj3 tubal) or (disease$ adj3 tubes)).tw. (649)<BR/>24 (oviduct$ adj3 damage$).tw. (26)<BR/>25 (oviduct$ adj3 fibrosis).tw. (3)<BR/>26 (disten$ adj3 oviduct$).tw. (5)<BR/>27 (occlu$ adj3 oviduct$).tw. (41)<BR/>28 (adhesion$ adj3 oviduct$).tw. (25)<BR/>29 ((Tubal adj3 obstruction$) or (Tube adj3 obstruction$)).tw. (1213)<BR/>30 1 and 29 (278)<BR/>31 or/1-28,30 (25812)<BR/>32 gynecologic surgical procedures/ or salpingectomy/ or salpingostomy/ (14627)<BR/>33 (surgery or surgical).tw. (1658696)<BR/>34 32 and 33 (9079)<BR/>35 laparoscopy/ or hand-assisted laparoscopy/ (56876)<BR/>36 Laparoscop$.tw. (134431)<BR/>37 Laparotomy/ (57049)<BR/>38 Laparotomy.tw. (46702)<BR/>39 electrosurgery/ or microsurgery/ (28040)<BR/>40 microsurg$.tw. (23216)<BR/>41 minilaparotom$.tw. (1149)<BR/>42 tubo-cornual anastomosis.tw. (3)<BR/>43 fimbrioplasty.tw. (78)<BR/>44 adhesiolysis.tw. (1860)<BR/>45 reconstruction.tw. (163756)<BR/>46 (recanalizing or recanalising).tw. (235)<BR/>47 (recanalisation or recanalization).tw. (12911)<BR/>48 (salpingostomy or salpingectomy).tw. (2173)<BR/>49 aspiration.tw. (79956)<BR/>50 electrocoagulatioaintern.tw. (2749)<BR/>51 Sclerotherapy/ (8628)<BR/>52 Sclerotherap$.tw. (7813)<BR/>53 emboli?ation.tw. (47816)<BR/>54 or/32,34-53 (552917)<BR/>55 31 and 54 (6793)<BR/>56 Clinical Trial/ (848860)<BR/>57 Randomized Controlled Trial/ (380154)<BR/>58 exp randomization/ (67586)<BR/>59 Single Blind Procedure/ (20772)<BR/>60 Double Blind Procedure/ (122634)<BR/>61 Crossover Procedure/ (43961)<BR/>62 Placebo/ (261129)<BR/>63 Randomi?ed controlled trial$.tw. (121529)<BR/>64 Rct.tw. (17856)<BR/>65 random allocation.tw. (1441)<BR/>66 randomly.tw. (296704)<BR/>67 randomly allocated.tw. (22974)<BR/>68 allocated randomly.tw. (2045)<BR/>69 (allocated adj2 random).tw. (734)<BR/>70 Single blind$.tw. (16181)<BR/>71 Double blind$.tw. (153400)<BR/>72 ((treble or triple) adj blind$).tw. (471)<BR/>73 placebo$.tw. (218534)<BR/>74 prospective study/ (302585)<BR/>75 or/56-74 (1662347)<BR/>76 case study/ (33245)<BR/>77 case report.tw. (287952)<BR/>78 abstract report/ or letter/ (933800)<BR/>79 or/76-78 (1248567)<BR/>80 75 not 79 (1622351)<BR/>81 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5341103)<BR/>82 80 not 81 (1508716)<BR/>83 55 and 82 (661)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-10-19 15:47:25 +1300" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2015-08-18 13:41:15 +1200" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 15:47:25 +1300" MODIFIED_BY="[Empty name]">
<P>(searched from 1806 to 19 October 2016) (Ovid platform)</P>
<P>1 exp Gynecological Disorders/ (1613)<BR/>2 tubal infertility.tw. (2)<BR/>3 tubal factor.tw. (4)<BR/>4 (disten$ adj3 tube).tw. (1)<BR/>5 tubal occlusion.tw. (5)<BR/>6 fallopian.tw. (46)<BR/>7 ((Tubal adj3 obstruction$) or (Tube adj3 obstruction$)).tw. (6)<BR/>8 2 or 3 or 4 or 5 or 6 or 7 (63)<BR/>9 1 and 8 (4)<BR/>10 8 or 9 (63)<BR/>11 exp Gynecology/ or exp Surgery/ (50237)<BR/>12 microsurg$.tw. (214)<BR/>13 Laparoscop$.tw. (393)<BR/>14 Laparotomy.tw. (121)<BR/>15 adhesiolysis.tw. (14)<BR/>16 reconstruction.tw. (8168)<BR/>17 (salpingostomy or salpingectomy).tw. (15)<BR/>18 aspiration.tw. (4129)<BR/>19 electrocoagulation.tw. (67)<BR/>20 emboli?ation.tw. (238)<BR/>21 (surgery or surgical).tw. (35051)<BR/>22 or/11-21 (82130)<BR/>23 10 and 22 (20)<BR/>24 random*.ti,ab,hw,id. (159256)<BR/>25 trial*.ti,ab,hw,id. (148083)<BR/>26 controlled stud*.ti,ab,hw,id. (10491)<BR/>27 placebo*.ti,ab,hw,id. (35395)<BR/>28 ((singl* or doubl* or trebl* or tripl*) and (blind* or mask*)).ti,ab,hw,id. (25155)<BR/>29 (cross over or crossover or factorial* or latin square).ti,ab,hw,id. (25065)<BR/>30 (assign* or allocat* or volunteer*).ti,ab,hw,id. (137432)<BR/>31 treatment effectiveness evaluation/ (20480)<BR/>32 mental health program evaluation/ (1970)<BR/>33 exp experimental design/ (52046)<BR/>34 "2000".md. (0)<BR/>35 or/24-34 (434710)<BR/>36 23 and 35 (1)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-10-19 15:48:24 +1300" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2015-08-18 13:42:12 +1200" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 15:48:24 +1300" MODIFIED_BY="[Empty name]">
<P>(searched from 1982 to 19 October 2016) (EBSCO platform)</P>
<TABLE COLS="3" ROWS="58">
<TR>
<TD>
<P>#</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
</TR>
<TR>
<TD>
<P>S57</P>
</TD>
<TD>
<P>S44 AND S56</P>
</TD>
<TD>
<P>200</P>
</TD>
</TR>
<TR>
<TD>
<P>S56</P>
</TD>
<TD>
<P>S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55</P>
</TD>
<TD>
<P>1,081,306</P>
</TD>
</TR>
<TR>
<TD>
<P>S55</P>
</TD>
<TD>
<P>TX allocat* random*</P>
</TD>
<TD>
<P>5,281</P>
</TD>
</TR>
<TR>
<TD>
<P>S54</P>
</TD>
<TD>
<P>(MH "Quantitative Studies")</P>
</TD>
<TD>
<P>14,919</P>
</TD>
</TR>
<TR>
<TD>
<P>S53</P>
</TD>
<TD>
<P>(MH "Placebos")</P>
</TD>
<TD>
<P>9,827</P>
</TD>
</TR>
<TR>
<TD>
<P>S52</P>
</TD>
<TD>
<P>TX placebo*</P>
</TD>
<TD>
<P>39,650</P>
</TD>
</TR>
<TR>
<TD>
<P>S51</P>
</TD>
<TD>
<P>TX random* allocat*</P>
</TD>
<TD>
<P>5,281</P>
</TD>
</TR>
<TR>
<TD>
<P>S50</P>
</TD>
<TD>
<P>(MH "Random Assignment")</P>
</TD>
<TD>
<P>41,699</P>
</TD>
</TR>
<TR>
<TD>
<P>S49</P>
</TD>
<TD>
<P>TX randomi* control* trial*</P>
</TD>
<TD>
<P>110,746</P>
</TD>
</TR>
<TR>
<TD>
<P>S48</P>
</TD>
<TD>
<P>TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )</P>
</TD>
<TD>
<P>857,082</P>
</TD>
</TR>
<TR>
<TD>
<P>S47</P>
</TD>
<TD>
<P>TX clinic* n1 trial*</P>
</TD>
<TD>
<P>190,012</P>
</TD>
</TR>
<TR>
<TD>
<P>S46</P>
</TD>
<TD>
<P>PT Clinical trial</P>
</TD>
<TD>
<P>79,719</P>
</TD>
</TR>
<TR>
<TD>
<P>S45</P>
</TD>
<TD>
<P>(MH "Clinical Trials+")</P>
</TD>
<TD>
<P>203,397</P>
</TD>
</TR>
<TR>
<TD>
<P>S44</P>
</TD>
<TD>
<P>S22 AND S43</P>
</TD>
<TD>
<P>1,006</P>
</TD>
</TR>
<TR>
<TD>
<P>S43</P>
</TD>
<TD>
<P>S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41</P>
</TD>
<TD>
<P>539,009</P>
</TD>
</TR>
<TR>
<TD>
<P>S42</P>
</TD>
<TD>
<P>TX salpingo neostom*</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>S41</P>
</TD>
<TD>
<P>TX recanalisation or TX recanalization</P>
</TD>
<TD>
<P>1,140</P>
</TD>
</TR>
<TR>
<TD>
<P>S40</P>
</TD>
<TD>
<P>TX salpingostomy or salpingectomy</P>
</TD>
<TD>
<P>231</P>
</TD>
</TR>
<TR>
<TD>
<P>S39</P>
</TD>
<TD>
<P>TX recanalizing or TX recanalising</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>S38</P>
</TD>
<TD>
<P>TX lysis N2 adhesion*</P>
</TD>
<TD>
<P>67</P>
</TD>
</TR>
<TR>
<TD>
<P>S37</P>
</TD>
<TD>
<P>TX reconstruction</P>
</TD>
<TD>
<P>19,742</P>
</TD>
</TR>
<TR>
<TD>
<P>S36</P>
</TD>
<TD>
<P>TX adhesiolysis</P>
</TD>
<TD>
<P>129</P>
</TD>
</TR>
<TR>
<TD>
<P>S35</P>
</TD>
<TD>
<P>TX fimbrioplasty</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>S34</P>
</TD>
<TD>
<P>TX tubo-cornual anastomosis</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>S33</P>
</TD>
<TD>
<P>TX excision</P>
</TD>
<TD>
<P>9,388</P>
</TD>
</TR>
<TR>
<TD>
<P>S32</P>
</TD>
<TD>
<P>TX minilaparotom*</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>S31</P>
</TD>
<TD>
<P>(MM "Microsurgery+")</P>
</TD>
<TD>
<P>1,269</P>
</TD>
</TR>
<TR>
<TD>
<P>S30</P>
</TD>
<TD>
<P>TX Laparotomy</P>
</TD>
<TD>
<P>4,259</P>
</TD>
</TR>
<TR>
<TD>
<P>S29</P>
</TD>
<TD>
<P>(MM "Laparotomy")</P>
</TD>
<TD>
<P>839</P>
</TD>
</TR>
<TR>
<TD>
<P>S28</P>
</TD>
<TD>
<P>TX microsurg*</P>
</TD>
<TD>
<P>2,853</P>
</TD>
</TR>
<TR>
<TD>
<P>S27</P>
</TD>
<TD>
<P>TX Laparoscop*</P>
</TD>
<TD>
<P>20,801</P>
</TD>
</TR>
<TR>
<TD>
<P>S26</P>
</TD>
<TD>
<P>(MH "Surgery, Laparoscopic+")</P>
</TD>
<TD>
<P>4,692</P>
</TD>
</TR>
<TR>
<TD>
<P>S25</P>
</TD>
<TD>
<P>TX surgical</P>
</TD>
<TD>
<P>160,422</P>
</TD>
</TR>
<TR>
<TD>
<P>S24</P>
</TD>
<TD>
<P>TX surgery</P>
</TD>
<TD>
<P>467,855</P>
</TD>
</TR>
<TR>
<TD>
<P>S23</P>
</TD>
<TD>
<P>(MM "Surgery, Gynecologic+")</P>
</TD>
<TD>
<P>6,174</P>
</TD>
</TR>
<TR>
<TD>
<P>S22</P>
</TD>
<TD>
<P>S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21</P>
</TD>
<TD>
<P>2,773</P>
</TD>
</TR>
<TR>
<TD>
<P>S21</P>
</TD>
<TD>
<P>TX disease* N3 tubal</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>S20</P>
</TD>
<TD>
<P>TX disease* N3 tubes</P>
</TD>
<TD>
<P>322</P>
</TD>
</TR>
<TR>
<TD>
<P>S19</P>
</TD>
<TD>
<P>TX Tube N3 lesion*</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>S18</P>
</TD>
<TD>
<P>TX tubes N3 lesion*</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>S17</P>
</TD>
<TD>
<P>TX Tubal N3 lesion*</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>S16</P>
</TD>
<TD>
<P>TX hydrosalpin*</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>S15</P>
</TD>
<TD>
<P>TX tubal N3 block*</P>
</TD>
<TD>
<P>13</P>
</TD>
</TR>
<TR>
<TD>
<P>S14</P>
</TD>
<TD>
<P>TX tube* N3 block*</P>
</TD>
<TD>
<P>115</P>
</TD>
</TR>
<TR>
<TD>
<P>S13</P>
</TD>
<TD>
<P>TX pelvic inflammatory</P>
</TD>
<TD>
<P>1,041</P>
</TD>
</TR>
<TR>
<TD>
<P>S12</P>
</TD>
<TD>
<P>TX peritubal N3 adhesion*</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>S11</P>
</TD>
<TD>
<P>TX fallopian</P>
</TD>
<TD>
<P>1,155</P>
</TD>
</TR>
<TR>
<TD>
<P>S10</P>
</TD>
<TD>
<P>TX adhesion* N3 tub*</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>S9</P>
</TD>
<TD>
<P>TX tubal occlusion</P>
</TD>
<TD>
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>S8</P>
</TD>
<TD>
<P>TX disten* N3 tube*</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>S7</P>
</TD>
<TD>
<P>TX tubal fibrosis</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>S6</P>
</TD>
<TD>
<P>TX tub* N3 damage</P>
</TD>
<TD>
<P>271</P>
</TD>
</TR>
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>(MM "Pelvic Inflammatory Disease")</P>
</TD>
<TD>
<P>416</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>TX tubal factor</P>
</TD>
<TD>
<P>113</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>TX tubal subfertility</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>TX tubal infertility</P>
</TD>
<TD>
<P>112</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>(MM "Fallopian Tube Diseases+")</P>
</TD>
<TD>
<P>268</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2016-11-28 23:53:56 +1300" MODIFIED_BY="Su Jen Chua" NO="7">
<TITLE MODIFIED="2015-08-25 18:24:23 +1200" MODIFIED_BY="Su Jen Chua">DARE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-28 23:53:56 +1300" MODIFIED_BY="Su Jen Chua">
<P>Cochrane Library (searched 24 November 2016)</P>
<P>All fields: "Fallopian tube obstruction" or "tubal factor" or "tubal flushing" or "tubal infertility" or "tubal inflation" or "tubal occlusion" or "tubal occlusion - proximal" or "tubal patency" or "tubal reconstruction" or "tubal subfertility" or "tube drainage" or "tuboplasty" or "Fallopian Tube Fixation" or "fallopian tubes" or "tubal anastomosis" or "tubal disorders" or "tubo-ovarian abcess" or "salpingectomy" or "Salpingitis-Physiopathology" or "salpingo-oopherectomy" or "Salpingolysis" or "*Salpingostomy" or "salpingotomy" or "Hydrosalpinx" or "hydrosalpingies" or "hydrosalpinges" or "falloscopy" or "laparoscopic salpingectomy" or "laparoscopic salpingoovolysis" or "laparoscopic salpingotomy" or "laparoscopic tubal fulguration" or "microsurgery" or "microscopic" or "microdiathermy" or "microlaparoscopy" or "hydrotubation"</P>
<P>(142 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2016-11-28 23:53:50 +1300" MODIFIED_BY="Su Jen Chua" NO="8">
<TITLE MODIFIED="2015-08-25 18:28:04 +1200" MODIFIED_BY="Su Jen Chua">http://www.clinicaltrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-28 23:53:50 +1300" MODIFIED_BY="Su Jen Chua">
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD>
<P>(Infertile</P>
<P>OR infertility</P>
<P>OR subfertile</P>
<P>OR subfertility) AND</P>
<P>(Tubal OR</P>
<P>tube</P>
<P>OR tubes</P>
<P>OR oviduct</P>
<P>OR oviducts)</P>
</TD>
<TD>
<P>Surgery</P>
<P>OR surgical</P>
<P>OR surgically</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P>(Infertile OR infertility OR subfertile OR subfertility) AND (Tubal OR tube OR tubes OR oviduct OR oviducts) AND (Surgery OR surgical OR surgically)</P>
<P>(searched 24 November 2016)</P>
<P>45 hits</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2017-01-03 01:05:42 +1300" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2017-01-03 01:05:42 +1300" MODIFIED_BY="[Empty name]">World Health Organization International Trials Registry Portal search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-29 01:47:02 +1300" MODIFIED_BY="Su Jen Chua">
<P>(searched 24 November 2016)</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD>
<P>(Subfertility</P>
<P>OR subfertile</P>
<P>OR infertility</P>
<P>OR infertile)</P>
<P/>
<P>AND</P>
<P/>
<P>(&#8220;Fallopian tube&#8221; OR &#8220;Fallopian tubes&#8221;</P>
<P>OR oviduct</P>
<P>OR oviducts</P>
<P>OR tubal)</P>
<P/>
<P>NOT male</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P>Subfertility AND tubal NOT male (0 trials)</P>
<P>Infertility AND tubal NOT male (11 trials)</P>
<P>Infertile AND tubal NOT male (11 duplicates)</P>
<P>Subfertile AND tubal NOT male (0 trials)</P>
<P>Subfertility AND oviduct* NOT male (0 trials)</P>
<P>Infertility AND oviduct* NOT male (1 trials)</P>
<P>Infertile AND oviduct* NOT male (1 duplicate)</P>
<P>Subfertile AND oviduct* NOT male (0 trials)</P>
<P>Subfertility AND Fallopian tube* NOT male (0 trials)</P>
<P>Infertility AND Fallopian tube* NOT male (2 trials)</P>
<P>Infertile AND Fallopian tube* NOT male (2 duplicate)</P>
<P>Subfertile AND Fallopian tube* NOT male (0)</P>
<P>28 hits (13 hits minus duplicates)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2016-11-24 22:13:22 +1300" MODIFIED_BY="Su Jen Chua" NO="10">
<TITLE MODIFIED="2015-08-25 18:41:15 +1200" MODIFIED_BY="Su Jen Chua">Web of Science search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-24 22:13:22 +1300" MODIFIED_BY="Su Jen Chua">
<P>Version 5.18, limited to Web of Science Core Collection database</P>
<P>Basic Search option</P>
<P>(searched 24 November 2016)</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>search tag:TOPIC</P>
<P/>
<P>&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or &#8220;salpingitis&#8221; OR</P>
<P>&#8220;tubal infertil*&#8221; OR &#8220;tubal subfertil*&#8221; OR</P>
<P>tubal factor OR &#8220;tubal fibrosis&#8221; OR (disten* NEAR/3 tube) OR (disten* NEAR/3 tubal) OR<BR/>&#8220;tubal occlusion&#8221; OR (occlusion NEAR/3 tubes) OR (occlusion NEAR/3 tube) OR ((tube NEAR/3 damage) or (tubal NEAR/3 damage)) OR (tube NEAR/3 damage) OR (adhesion* NEAR/3 tubal) OR</P>
<P>(adhesion* NEAR/3 tube) OR (adhesion* NEAR/3 tubes) OR fallopian OR (peritubal NEAR/3 adhesion*) OR (tube NEAR/3 block*) OR (tubal NEAR/3 block*) OR (tubes NEAR/3 block*) OR hydrosalpin* OR ((Tubal NEAR/3 lesion*) or (Tube NEAR/3 lesion*)) OR ((disease* NEAR/3 tubal) or (disease* NEAR/3 tubes)) OR (oviduct* NEAR/3 damage*) OR (oviduct* NEAR/3 fibrosis) OR (disten* NEAR/3 oviduct*) OR (occlu* NEAR/3 oviduct*) OR (adhesion* NEAR/3 oviduct*) OR (((Tubal NEAR/3 obstruction*) or (Tube NEAR/3 obstruction*)) AND (&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or salpingitis))</P>
</TD>
<TD>
<P>search tag: TOPIC</P>
<P/>
<P>((&#8220;gynecologic surgical procedures&#8221; or salpingectomy or salpingostomy) AND (surgery or surgical)) OR (&#8220;gynecologic surgical procedures&#8221; or salpingectomy or salpingostomy) or &#8220;hand-assisted laparoscopy&#8220; OR Laparoscop* OR Laparotomy OR electrosurgery or microsurg* OR minilaparotom* OR tubo-cornual anastomosis OR fimbrioplasty OR adhesiolysis OR reconstruction OR (recanalizing or recanalising) OR (recanalisation or recanalization) OR (salpingostomy or salpingectomy) OR aspiration OR electrocoagulation OR Sclerotherapy OR Sclerotherap* OR emboli?ation</P>
</TD>
<TD>
<P>search tag: TOPIC</P>
<P/>
<P>((randomi* NEAR/1 &#8220;controlled trial*&#8221;) OR &#8220;controlled clinical trial&#8221; OR &#8220;random allocation*&#8221; OR &#8220;double-blind&#8221; OR &#8220;single-blind&#8221; OR (clin* NEAR/25 trial*) OR ((singl* or doubl* or tripl* or trebl*) NEAR/25 (blind* or mask*)) OR</P>
<P>placebo* OR &#8220;Research design&#8221;) NOT (animal* not human*)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P>The RCT filter was adapted from the Medline RCT filter provided by Cochrane (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>)</P>
<P>(193 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2016-11-24 22:18:06 +1300" MODIFIED_BY="Su Jen Chua" NO="11">
<TITLE MODIFIED="2015-08-25 18:58:43 +1200" MODIFIED_BY="Su Jen Chua">OpenGrey search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-24 22:18:06 +1300" MODIFIED_BY="Su Jen Chua">
<P>(searched 24 November 2016)</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or &#8220;salpingitis&#8221; OR</P>
<P>&#8220;tubal infertil*&#8221; OR &#8220;tubal subfertil*&#8221; OR</P>
<P>tubal factor OR &#8220;tubal fibrosis&#8221; OR (disten* NEAR/3 tube) OR (disten* NEAR/3 tubal) OR<BR/>&#8220;tubal occlusion&#8221; OR (occlusion NEAR/3 tubes) OR (occlusion NEAR/3 tube) OR ((tube NEAR/3 damage) or (tubal NEAR/3 damage)) OR (tube NEAR/3 damage) OR (adhesion* NEAR/3 tubal) OR</P>
<P>(adhesion* NEAR/3 tube) OR (adhesion* NEAR/3 tubes) OR fallopian OR (peritubal NEAR/3 adhesion*) OR (tube NEAR/3 block*) OR (tubal NEAR/3 block*) OR (tubes NEAR/3 block*) OR hydrosalpin* OR ((Tubal NEAR/3 lesion*) or (Tube NEAR/3 lesion*)) OR ((disease* NEAR/3 tubal) or (disease* NEAR/3 tubes)) OR (oviduct* NEAR/3 damage*) OR (oviduct* NEAR/3 fibrosis) OR (disten* NEAR/3 oviduct*) OR (occlu* NEAR/3 oviduct*) OR (adhesion* NEAR/3 oviduct*) OR (((Tubal NEAR/3 obstruction*) or (Tube NEAR/3 obstruction*)) AND (&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or salpingitis))</P>
</TD>
<TD VALIGN="TOP">
<P>((&#8220;gynecologic surgical procedures&#8221; or salpingectomy or salpingostomy) AND (surgery or surgical)) OR (&#8220;gynecologic surgical procedures&#8221; or salpingectomy or salpingostomy) or &#8220;hand-assisted laparoscopy&#8220; OR Laparoscop* OR Laparotomy OR electrosurgery or microsurg* OR minilaparotom* OR tubo-cornual anastomosis OR fimbrioplasty OR adhesiolysis OR reconstruction OR (recanalizing or recanalising) OR (recanalisation or recanalization) OR (salpingostomy or salpingectomy) OR aspiration OR electrocoagulation OR Sclerotherapy OR Sclerotherap* OR embolization OR embolization</P>
</TD>
<TD VALIGN="TOP">
<P>((randomi* NEAR/1 &#8220;controlled trial*&#8221;) OR &#8220;controlled clinical trial&#8221; OR &#8220;random allocation*&#8221; OR &#8220;double-blind&#8221; OR &#8220;single-blind&#8221; OR (clin* NEAR/25 trial*) OR ((singl* or doubl* or tripl* or trebl*) NEAR/25 (blind* or mask*)) OR</P>
<P>placebo* OR &#8220;Research design&#8221;) NOT (animal* not human*)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<P>The RCT filter was adapted from the Medline RCT filter provided by Cochrane (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>)</P>
<P>(&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or &#8220;salpingitis&#8221; OR &#8220;tubal infertil*&#8221; OR &#8220;tubal subfertil*&#8221; OR tubal factor OR &#8220;tubal fibrosis&#8221; OR (disten* NEAR/3 tube) OR (disten* NEAR/3 tubal) OR &#8220;tubal occlusion&#8221; OR (occlusion NEAR/3 tubes) OR (occlusion NEAR/3 tube) OR ((tube NEAR/3 damage) or (tubal NEAR/3 damage)) OR (tube NEAR/3 damage) OR (adhesion* NEAR/3 tubal) OR (adhesion* NEAR/3 tube) OR (adhesion* NEAR/3 tubes) OR fallopian OR (peritubal NEAR/3 adhesion*) OR (tube NEAR/3 block*) OR (tubal NEAR/3 block*) OR (tubes NEAR/3 block*) OR hydrosalpin* OR ((Tubal NEAR/3 lesion*) or (Tube NEAR/3 lesion*)) OR ((disease* NEAR/3 tubal) or (disease* NEAR/3 tubes)) OR (oviduct* NEAR/3 damage*) OR (oviduct* NEAR/3 fibrosis) OR (disten* NEAR/3 oviduct*) OR (occlu* NEAR/3 oviduct*) OR (adhesion* NEAR/3 oviduct*) OR (((Tubal NEAR/3 obstruction*) or (Tube NEAR/3 obstruction*)) AND (&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or salpingitis))) AND (((&#8220;gynecologic surgical procedures&#8221; or salpingectomy or salpingostomy) AND (surgery or surgical)) OR (&#8220;gynecologic surgical procedures&#8221; or salpingectomy or salpingostomy) or &#8220;hand-assisted laparoscopy&#8220; OR Laparoscop* OR Laparotomy OR electrosurgery or microsurg* OR minilaparotom* OR tubo-cornual anastomosis OR fimbrioplasty OR adhesiolysis OR reconstruction OR (recanalizing or recanalising) OR (recanalisation or recanalization) OR (salpingostomy or salpingectomy) OR aspiration OR electrocoagulation OR Sclerotherapy OR Sclerotherap* OR embolization OR embolization ) AND (((randomi* NEAR/1 &#8220;controlled trial*&#8221;) OR &#8220;controlled clinical trial&#8221; OR &#8220;random allocation*&#8221; OR &#8220;double-blind&#8221; OR &#8220;single-blind&#8221; OR (clin* NEAR/25 trial*) OR ((singl* or doubl* or tripl* or trebl*) NEAR/25 (blind* or mask*)) OR placebo* OR &#8220;Research design&#8221;) NOT (animal* not human*))</P>
<P>0 hits</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2016-11-24 22:21:00 +1300" MODIFIED_BY="Su Jen Chua" NO="12">
<TITLE MODIFIED="2015-08-25 19:02:18 +1200" MODIFIED_BY="Su Jen Chua">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-24 22:21:00 +1300" MODIFIED_BY="Su Jen Chua">
<P>(searched 24 November 2016)</P>
<P>Limited to the LILACs database using the "Controlled Clinical Trial" tag as provided by the search portal</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(TW:Fallopian Tube Disease*) or (TW:tubal infertility)</P>
<P>OR (TW:tubal subfertility)</P>
<P>OR (TW:tubal factor*) or (TW:Pelvic Inflammatory Disease) OR (TW:tubal factor infertil*) OR (TW:tubal factor subfertil*) OR (TW:tubal damage) OR (TW:tubal fibrosis) OR (TW:tube damage*) OR (TW:tube fibrosis)</P>
<P>OR (TW:oviduct* damage*) OR (TW:oviduct* fibrosis) OR (TW:tubal distension*)</P>
<P>OR (TW:tube distension*) OR (TW:distended tube) OR (TW:distended tubes) OR (TW:distended oviduct*) OR (TW:oviduct distension*) OR (TW:tubal occlusion) OR</P>
<P>(TW:occluded tube) OR (TW:occluded tubes) OR (TW:tube occlu*)</P>
<P>OR (TW:occluded oviduct*) OR (TW:oviduct occlu*) OR (TW:tubal adhesion*) OR (TW:tube adhesion*) OR (TW:oviduct adhesion*)</P>
</TD>
<TD VALIGN="TOP">
<P>(TW:Laparoscop*) or (TW:Microsurg*) or (TW:tubal surgery) OR</P>
<P>(TW:surgery oviduct*) OR (TW:surgical* oviduct*) OR (TW:infertility surgery) OR</P>
<P>(TW:surgery infertil*) OR</P>
<P>(TW:surgery subfertil*) OR</P>
<P>(TW:surgical* infertil*) OR</P>
<P>(TW:surgical* subfertil*)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<P>((TW:Fallopian Tube Disease*) or (TW:tubal infertility) OR (TW:tubal subfertility) OR (TW:tubal factor*) or (TW:Pelvic Inflammatory Disease) OR (TW:tubal factor infertil*) OR (TW:tubal factor subfertil*) OR (TW:tubal damage) OR (TW:tubal fibrosis) OR (TW:tube damage*) OR (TW:tube fibrosis) OR (TW:oviduct* damage*) OR (TW:oviduct* fibrosis) OR (TW:tubal distension*) OR (TW:tube distension*) OR (TW:distended tube) OR (TW:distended tubes) OR (TW:distended oviduct*) OR (TW:oviduct distension*) OR (TW:tubal occlusion) OR (TW:occluded tube) OR (TW:occluded tubes) OR (TW:tube occlu*) OR (TW:occluded oviduct*) OR (TW:oviduct occlu*) OR (TW:tubal adhesion*) OR (TW:tube adhesion*) OR (TW:oviduct adhesion*)) AND ((TW:Laparoscop*) or (TW:Microsurg*) or (TW:tubal surgery) OR (TW:surgery oviduct*) OR (TW:surgical* oviduct*) OR (TW:infertility surgery) OR (TW:surgery infertil*) OR (TW:surgery subfertil*) OR (TW:surgical* infertil*) OR (TW:surgical* subfertil*))</P>
<P>5 hits</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-13" MODIFIED="2016-11-24 22:23:37 +1300" MODIFIED_BY="Su Jen Chua" NO="13">
<TITLE MODIFIED="2015-08-25 18:35:52 +1200" MODIFIED_BY="Su Jen Chua">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-24 22:23:37 +1300" MODIFIED_BY="Su Jen Chua">
<P>(From 2012 to 24 November 2016) (limit to last 5 years)</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD>
<P>Fallopian Tube Disease*[tw] or tubal infertility[all] OR tubal subfertility[all] OR tubal factor*[all] or Pelvic Inflammatory Disease[tw] OR tubal factor infertil*[all] OR tubal factor subfertil*[all] OR tubal damage[all] OR tubal fibrosis[all] OR tube damage*[all] OR tube fibrosis[all] OR oviduct* damage*[all] OR oviduct* fibrosis[all] OR tubal distension*[all] OR tube distension*[all] OR distended tube[all] OR distended tubes[all] OR distended oviduct*[all] OR oviduct distension* [all] OR tubal occlusion[all] OR occluded tube[all] OR occluded tubes[all] OR tube occlu* [all] OR occluded oviduct*[all] OR oviduct occlu* [all] OR tubal adhesion*[all] OR tube adhesion*[all] OR oviduct adhesion*[all] OR hydrosalpin* [all] OR fallopian [all]</P>
<P>OR oviducts)Fallopian Tube Disease*[tw] or tubal infertility[all] OR tubal subfertility[all] OR tubal factor*[all] or Pelvic Inflammatory Disease[tw] OR tubal factor infertil*[all] OR tubal factor subfertil*[all] OR tubal damage[all] OR tubal fibrosis[all] OR tube damage*[all] OR tube fibrosis[all] OR oviduct* damage*[all] OR oviduct* fibrosis[all] OR tubal distension*[all] OR tube distension*[all] OR distended tube[all] OR distended tubes[all] OR distended oviduct*[all] OR oviduct distension* [all] OR tubal occlusion[all] OR occluded tube[all] OR occluded tubes[all] OR tube occlu* [all] OR occluded oviduct*[all] OR oviduct occlu* [all] OR tubal adhesion*[all] OR tube adhesion*[all] OR oviduct adhesion*[all] OR hydrosalpin* [all] OR fallopian [all]</P>
</TD>
<TD>
<P>Laparoscop*[tw] or Microsurg*[tw] or laparotomy*[tw] or aspiration [tw] or tubal surgery[all] OR surgery oviduct*[all] OR surgical* oviduct*[all] OR infertility surgery[all] OR surgery infertil*[all] OR surgery subfertil*[all] OR surgical* infertil*[all] OR surgical* subfertil*[all] OR adhesiolysis [all] OR salpingostomy [all] OR salpingectomy [all] OR embolisation[all] OR embolization[all] OR reconstruction[all]</P>
<P>OR surgical</P>
<P>OR surgically</P>
</TD>
<TD>
<P>(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tw] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P>(Fallopian Tube Disease*[tw] or tubal infertility[all] OR tubal subfertility[all] OR tubal factor*[all] or Pelvic Inflammatory Disease[tw] OR tubal factor infertil*[all] OR tubal factor subfertil*[all] OR tubal damage[all] OR tubal fibrosis[all] OR tube damage*[all] OR tube fibrosis[all] OR oviduct* damage*[all] OR oviduct* fibrosis[all] OR tubal distension*[all] OR tube distension*[all] OR distended tube[all] OR distended tubes[all] OR distended oviduct*[all] OR oviduct distension* [all] OR tubal occlusion[all] OR occluded tube[all] OR occluded tubes[all] OR tube occlu* [all] OR occluded oviduct*[all] OR oviduct occlu* [all] OR tubal adhesion*[all] OR tube adhesion*[all] OR oviduct adhesion*[all] OR hydrosalpin* [all] OR fallopian [all]) AND (Laparoscop*[tw] or Microsurg*[tw] or laparotomy*[tw] or aspiration [tw] or tubal surgery[all] OR surgery oviduct*[all] OR surgical* oviduct*[all] OR infertility surgery[all] OR surgery infertil*[all] OR surgery subfertil*[all] OR surgical* infertil*[all] OR surgical* subfertil*[all] OR adhesiolysis [all] OR salpingostomy [all] OR salpingectomy [all] OR embolisation[all] OR embolization[all] OR reconstruction[all]) AND ((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tw] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh]))</P>
<P>This search utilised the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)</P>
<P>(76 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-14" MODIFIED="2016-11-29 01:47:09 +1300" MODIFIED_BY="Su Jen Chua" NO="14">
<TITLE MODIFIED="2015-08-25 19:23:40 +1200" MODIFIED_BY="Su Jen Chua">Google Scholar search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-29 01:47:09 +1300" MODIFIED_BY="Su Jen Chua">
<P>The Google Scholar search was run via the Publish or Perish program. (<LINK REF="REF-Harzing-2007" TYPE="REFERENCE">Harzing 2007</LINK>)</P>
<P>(searched 24 November 2016)</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>(tubal OR fallopian OR oviduct) AND (infertility OR infertile OR subfertile OR subfertility)</P>
<P/>
<P>NOT male</P>
<P>NOT men</P>
<P>NOT animal</P>
</TD>
<TD VALIGN="TOP">
<P>surgery</P>
</TD>
<TD VALIGN="TOP">
<P>Random</P>
</TD>
<TD VALIGN="TOP">
<P>pregnancy</P>
</TD>
</TR>
</TABLE>
<P>Year of publication between: 2016 and 2016</P>
<P>1. Search field (all of the words): tubal, infertility, surgery, random, pregnancy AND Search Field (none of the words): male, men, animal (107 hits)</P>
<P>2. Search field (all of the words): tubal, infertile, surgery, random, pregnancy AND Search Field (none of the words): male, men, animal (87 hits)</P>
<P>3. Search field (all of the words): tubal, subfertile, surgery, random, pregnancy AND Search Field (none of the words): male, men, animal (11 hits)</P>
<P>4. Search field (all of the words): tubal, subfertility, surgery, random, pregnancy AND Search Field (none of the words):male, men, animal (106 hits)</P>
<P>5. Search field (all of the words): fallopian, infertility, surgery, random, pregnancy AND, Search field (none of the words): male, men, animal (77 hits)</P>
<P>6. Search field (all of the words): fallopian, infertile, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (61 hits)</P>
<P>7. Search field (all of the words): fallopian, subfertile, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (9 hits)</P>
<P>8. Search field (all of the words): fallopian, subfertility, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (79 hits)</P>
<P>9. Search field (all of the words): oviduct, infertility, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (5 hits)</P>
<P>10. Search field (all of the words): oviduct, infertile, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (3 hits)</P>
<P>11. Search field (all of the words): oviduct, subfertile, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (0 hits)</P>
<P>12. Search field (all of the words):oviduct, subfertility, surgery, random, pregnancy AND Search field (none of the words): male, men, animal (5 hits)</P>
<P>Total: 550 hits (146 hits excluding duplicates)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-15" MODIFIED="2016-11-24 22:34:20 +1300" MODIFIED_BY="Su Jen Chua" NO="15">
<TITLE MODIFIED="2016-11-24 22:32:01 +1300" MODIFIED_BY="Su Jen Chua">ProQuest Dissertations &amp; Theses Global search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-24 22:34:20 +1300" MODIFIED_BY="Su Jen Chua">
<P>Searched 24th November 2016</P>
<TABLE COLS="4" ROWS="2">
<TR>
<TD>
<P>PATIENT</P>
</TD>
<TD>
<P>INTERVENTION</P>
</TD>
<TD>
<P>COMPARATOR</P>
</TD>
<TD>
<P>OUTCOME</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or salpingitis OR</P>
<P>&#8220;tubal infertil*&#8221; OR&#8221; tubal subfertil*&#8221; OR</P>
<P>&#8220;tubal factor&#8221; OR &#8220;tubal fibrosis&#8221; OR (disten* NEAR/3 tube) OR (disten* NEAR/3 tubal) OR &#8220;tubal occlusion&#8221; OR (occlusion NEAR/3 tubes) OR (occlusion NEAR/3 tube) OR ((tube NEAR/3 damage) or (tubal NEAR/3 damage)) OR (tube NEAR/3 damage) OR (adhesion* NEAR/3 tubal) OR</P>
<P>(adhesion* NEAR/3 tube) OR (adhesion* NEAR/3 tubes) OR fallopian OR (peritubal NEAR/3 adhesion*) OR (tube NEAR/3 block*) OR (tubal NEAR/3 block*) OR (tubes NEAR/3 block*) OR hydrosalpin* OR ((Tubal NEAR/3 lesion*) or (Tube NEAR/3 lesion*)) OR ((disease* NEAR/3 tubal) or (disease* NEAR/3 tubes)) OR (oviduct* NEAR/3 damage*) OR (oviduct* NEAR/3 fibrosis) OR (disten* NEAR/3 oviduct*) OR (occlu* NEAR/3 oviduct*) OR (adhesion* NEAR/3 oviduct*) OR (((Tubal NEAR/3 obstruction*) or (Tube NEAR/3 obstruction*)) AND (exp fallopian tube diseases or pelvic inflammatory disease or salpingitis)) NOT male</P>
<P/>
<P>NOT male</P>
</TD>
<TD VALIGN="TOP">
<P>((&#8220;gynecologic surgical procedure*&#8221; or salpingectomy or salpingostomy) AND (surgery or surgical)) OR (&#8220;gynecologic surgical procedure*&#8221; or salpingectomy or salpingostomy) OR &#8220;hand-assisted laparoscopy&#8221; OR Laparoscop* OR Laparotomy OR electrosurgery or microsurg* OR minilaparotom* OR tubo-cornual anastomosis OR fimbrioplasty OR adhesiolysis OR reconstruction OR (recanalizing or recanalising) OR (recanalisation or recanalization) OR (salpingostomy or salpingectomy) OR aspiration OR electrocoagulation OR Sclerotherap* OR emboli?ation</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>((randomi* NEAR/1 &#8220;controlled trial*&#8221;) OR &#8220;controlled clinical trial&#8221; OR &#8220;random allocation*&#8221; OR &#8220;double-blind&#8221; OR &#8220;single-blind&#8221; OR (clin* NEAR25 trial*) OR ((singl* or doubl* or tripl* or trebl*) NEAR/25 (blind* or mask*)) OR</P>
<P>placebo* OR &#8220;Research design&#8221;) NOT (animal* not human*)</P>
</TD>
<TD VALIGN="TOP">
<P>Pregnan* OR birth*</P>
</TD>
</TR>
</TABLE>
<P>(&#8220;fallopian tube disease*&#8221; or &#8220;pelvic inflammatory disease&#8221; or salpingitis OR &#8220;tubal infertil*&#8221; OR&#8221; tubal subfertil*&#8221; OR &#8220;tubal factor&#8221; OR &#8220;tubal fibrosis&#8221; OR (disten* NEAR/3 tube) OR (disten* NEAR/3 tubal) OR &#8220;tubal occlusion&#8221; OR (occlusion NEAR/3 tubes) OR (occlusion NEAR/3 tube) OR ((tube NEAR/3 damage) or (tubal NEAR/3 damage)) OR (tube NEAR/3 damage) OR (adhesion* NEAR/3 tubal) OR (adhesion* NEAR/3 tube) OR (adhesion* NEAR/3 tubes) OR fallopian OR (peritubal NEAR/3 adhesion*) OR (tube NEAR/3 block*) OR (tubal NEAR/3 block*) OR (tubes NEAR/3 block*) OR hydrosalpin* OR ((Tubal NEAR/3 lesion*) or (Tube NEAR/3 lesion*)) OR ((disease* NEAR/3 tubal) or (disease* NEAR/3 tubes)) OR (oviduct* NEAR/3 damage*) OR (oviduct* NEAR/3 fibrosis) OR (disten* NEAR/3 oviduct*) OR (occlu* NEAR/3 oviduct*) OR (adhesion* NEAR/3 oviduct*) OR (((Tubal NEAR/3 obstruction*) or (Tube NEAR/3 obstruction*)) AND (exp fallopian tube diseases or pelvic inflammatory disease or salpingitis)) NOT male) AND (((&#8220;gynecologic surgical procedure*&#8221; or salpingectomy or salpingostomy) AND (surgery or surgical)) OR (&#8220;gynecologic surgical procedure*&#8221; or salpingectomy or salpingostomy) OR &#8220;hand-assisted laparoscopy&#8221; OR Laparoscop* OR Laparotomy OR electrosurgery or microsurg* OR minilaparotom* OR tubo-cornual anastomosis OR fimbrioplasty OR adhesiolysis OR reconstruction OR (recanalizing or recanalising) OR (recanalisation or recanalization) OR (salpingostomy or salpingectomy) OR aspiration OR electrocoagulation OR Sclerotherap* OR emboli?ation ) AND (Pregnan* OR birth*) AND (((controli* NEAR/1 &#8220;controlled trial*&#8221;) OR &#8220;controlled clinical trial&#8221; OR &#8220;control allocation*&#8221; OR &#8220;double-blind&#8221; OR &#8220;single-blind&#8221; OR (clin* NEAR25 trial*) OR ((singl* or doubl* or tripl* or trebl*) NEAR/25 (blind* or mask*)) OR placebo* OR &#8220;Research design&#8221;) NOT (animal* not human*))</P>
<P>The RCT filter was adapted from the Medline RCT filter provided by Cochrane (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>)</P>
<P>132 hits</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-16" MODIFIED="2017-01-05 16:31:29 +1300" MODIFIED_BY="[Empty name]" NO="16">
<TITLE MODIFIED="2017-01-03 01:06:24 +1300" MODIFIED_BY="[Empty name]">ESHRE and ASRM search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-05-21 19:16:20 +1200" MODIFIED_BY="Su Jen Chua">
<P>Handsearching of the ESHRE 2007, ESHRE 2015 and ASRM 2008 conference abstracts as these are not covered by the search of the Gynaecology and Fertility Group specialised register.</P>
<OL>
<LI>ESHRE 2007 (2)</LI>
<OL>
<LI>Gordts S, Campo R, Puttemans P, Valkenburg M, Brosens I, Gordts S. Microsurgical reversal of tubal sterilisation: to be preferred? Hum Reprod. 2007;22(Suppl 1):i227.</LI>
<LI>Hotineanu AL, Moshin VN, Hotineanu AV, Croitor ME. The effect of the proximal tubal &#8220;clamping&#8221; prior to the IVF in patients with distal tubal occlusion. Hum Reprod. 2007;22(Suppl 1):i126.</LI>
</OL>
<LI>ASRM 2008 (5)</LI>
<OL>
<LI>Fukuda A, Hamada A, Sawabe M, Sonoda M, Nakaoka Y, Morimoto Y. Pregnancy rate of bilateral tubal occlusion patients by IVF improves after recovery of tubal patency by falloposcopic tuboplasty. Fertility and sterility. 2008;90(Supplement):S155.</LI>
<LI>Poncelet C, Ducarme G, Yazbeck C, Uzan M, Madelenat P, Carbonnel M. Efficacy and safety of transient ovariopexy in severe endometriotic patients. A ten year experience. . Fertility and sterility. 2008;90(Supplement):S167-8.</LI>
<LI>Sawabe M, Fukuda A, Hamada A, Sonoda M, Nakaoka Y, Morimoto Y. Experience of 1000 falloposcopic tuboplasty (FT) cases: FT is a novel, patient friendly and effective regimen for tubal factor infertility before ART. Fertility and sterility. 2008;90(Supplement):S40.</LI>
<LI>Jindal UN, Verma YB, Sodhi S, Verma S. Comparative evaluation of laparoscopy and endometrial polymerase chain reaction for the diagnosis of female genital tuberculosis in infertile women in India. Fertility and sterility. 2008;90(Supplement):S152.</LI>
<LI>Hirano Y, Shibahara H, Shimada K, Suzuki T, Takamizawa S, Suzuki M. Clinical role of transvaginal hydrolaparoscopy for the diagnosis of early stage endometriosis. Fertility and sterility. 2008;90(Supplement):S441.</LI>
</OL>
<LI>ESHRE 2015 (3)</LI>
<OL>
<LI>Chu J, Harb HM, Gallos ID, Dhillon RK, Al-Rshoud FM, Robinson L, et al. Salpingostomy in the treatment of hydrosalpinx: a systematic review and meta-analysis. Hum Reprod. 2015;30(Supp 1):i448.</LI>
<LI>Wang XR, Bao HC, Hao CF. Core-pulling Salpingectomy: A Novel Surgical for Hydrosalpinx before IVF-ET. Hum Reprod. 2015;30(Supp 1):i33-4.</LI>
<LI>Lind T, Olofsson JI, Holte J, Hadziosmanovic N, Berglund L, Gudmundsson J, et al. Reduced clinical pregnancy rates by ART in women with a history of unilateral oophorectomy. Results of a large multi-center cohort study. Hum Reprod. 2015;30(Supp 1):i33.</LI>
</OL>
</OL>
<P>Total = 10 abstracts</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-17" MODIFIED="2016-02-23 16:25:58 +1300" MODIFIED_BY="Su Jen Chua" NO="17">
<TITLE MODIFIED="2016-02-23 16:21:50 +1300" MODIFIED_BY="Su Jen Chua">Reference lists of included trials and related reviews</TITLE>
<APPENDIX_BODY MODIFIED="2016-02-23 16:25:58 +1300" MODIFIED_BY="Su Jen Chua">
<P>1. Boer-Meisel, ME, te Velde, ER, Habbema, JD &amp; Kardaun, JW 1986, 'Predicting the pregnancy outcome in patients treated for hydrosalpinx: a prospective study', Fertil Steril, vol. 45, no. 1, Jan, pp. 23-29.</P>
<P>2. Vasquez, G, Boeckx, W &amp; Brosens, I 1995, 'Prospective study of tubal mucosal lesions and fertility in hydrosalpinges', Hum Reprod, vol. 10, no. 5, May, pp. 1075-1078.</P>
<P>3. Marcoux, S, Maheux, R &amp; Berube, S 1997, 'Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis', N Engl J Med, vol. 337, no. 4, Jul 24, pp. 217-222.</P>
<P>4. Hughes, EG, Fedorkow, DM &amp; Collins, JA 1993, 'A quantitative overview of controlled trials in endometriosis-associated infertility', Fertil Steril, vol. 59, no. 5, May, pp. 963-970.</P>
<P>5. Parazzini, F 1999, 'Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi', Hum Reprod, vol. 14, no. 5, May, pp. 1332-1334.</P>
<P>6. Bontis JN, Dinas KD. Management of hydrosalpinx: reconstructive surgery or IVF? Ann NY Acad Sci 2000;900:260 &#8211;71.</P>
<P>7. Murray DL, Sagoskin AW, Widra EA, Levy MJ. The adverse effect of hydrosalpinges on in vitro fertilization pregnancy rates and the benefit of surgical correction. Fertil Steril 1998;69:41&#8211;5.</P>
<P>8. Sagoskin AW, Lessey BA, Mottla GL, Richter KS, Chetkowski RJ, Chang AS, et al. Salpingectomy or proximal tubal occlusion of unilateral hydrosalpinx increases the potential for spontaneous pregnancy. Hum Reprod 2003;18:2634 &#8211;7.</P>
<P>9. Nackley AC, Muasher SJ. The significance of hydrosalpinx in in vitro fertilization. Fertil Steril 1998;69:373&#8211;84.</P>
<P>10. Strandell A, Lindhard A. Why does hydrosalpinx reduce fertility? The importance of hydrosalpinx fluid. Hum Reprod 2002;17:1141&#8211;5.</P>
<P>11. Eytan O, Azem F, Gull I, Wolman I, Elad D, Jaffa AJ. The mechanism of hydrosalpinx in embryo implantation. Hum Reprod 2001;16:2662&#8211;7.</P>
<P>12. Bildirici I, Bukulmez O, Ensari A, Yarali H, Gurgan T. A prospective evaluation of the effect of salpingectomy on endometrial receptivity in cases of women with communicating hydrosalpinges. Hum Reprod 2001;16:2422&#8211; 6.</P>
<P>13. Zeyneloglu HB. Hydrosalpinx and assisted reproduction: options andrationale for treatment. Curr Opin Obstet Gynecol 2001;13:281&#8211;6.</P>
<P>14. Dechaud H. Hydrosalpinx and ART: hydrosalpinges suitable for salpingectomy before IVF. Hum Reprod 2000;15:2464&#8211;5 </P>
<P>15. Choe J, Check JH. Salpingectomy for unilateral hydrosalpinx may improve in vivo fecundity. Gynecol Obstet Invest 1999;48:285&#8211;7.</P>
<P>16. Barmat LI, Rauch E, Spandorfer S, Kowalik A, Sills ES, Schattman G, et al. The effect of hydrosalpinges on IVF-ET outcome. J Assist Reprod Genet 1999;16:350&#8211;4.</P>
<P>17. Camus E, Poncelet C, Goffinet F, Wainer B, Merlet F, Nisand I, et al. Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. Hum Reprod 1999;14:1243&#8211;9.</P>
<P>17 articles identified</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-18" MODIFIED="2016-08-20 14:50:11 +1200" MODIFIED_BY="Su Jen Chua" NO="18">
<TITLE MODIFIED="2016-07-18 16:57:22 +1200" MODIFIED_BY="Helen E Nagels">Data extraction</TITLE>
<APPENDIX_BODY MODIFIED="2016-08-20 14:50:11 +1200" MODIFIED_BY="Su Jen Chua">
<P>The following information was extracted from the studies selected for the review:</P>
<P>
<I>
<B>Trial characteristics</B>
</I>
<BR/>
<I>1. Method of randomisation</I>
<BR/>a. Third-party randomisation: e.g. computer, telephone randomisation.<BR/>b. True randomisation by trialist: e.g. sequentially numbered, sealed, opaque envelopes, register, on-site computer system.<BR/>c. Method not stated.<BR/>
<BR/>
<I>2. Study design</I>
<BR/>a. Cross-over or parallel design.<BR/>b. Duration of follow up.<BR/>c. Type of follow up.<BR/>
<BR/>
<I>3. Size of the studies</I>
<BR/>a. Number of women recruited.<BR/>b. Number of women randomised.<BR/>c. Number of women excluded.<BR/>d. Number of women analysed.<BR/>e. Number of women lost to follow up.<BR/>f. Details of drop-outs given.<BR/>g. Duration of follow up.<BR/>
<BR/>
<I>4. Study setting</I>
<BR/>a. Single or multi- centred.<BR/>b. Location.<BR/>c. Timing.<BR/>
<BR/>
<I>5. Analysis</I>
<BR/>a. Sample size with power calculation.<BR/>b. Whether or not analysed by intention-to-treat:<BR/>b1. done;<BR/>b2. not done, but possible;<BR/>b3. not possible;<BR/>b4. uncertain.<BR/>
<BR/>
<I>6. The extent to which the Consolidated Standards of Reporting Trials criteria (CONSORT) are met.<BR/>
</I>
<BR/>
<I>
<B>Characteristics of the study participants</B>
</I>
<B>
<BR/>
</B>a. Subfertile couples with at least one year&#8217;s duration of infertility.<BR/>b. Females under forty years of age.<BR/>c. Minor/grade I, moderate/grade II, or severe/grade III tubal damage confirmed prior to tubal surgery by means of HSG or laparoscopy.<BR/>d. Women who have had tubal surgery for minor/grade I, moderate/grade II, or severe/grade III tubal damage carried out following investigation.<BR/>
<BR/>
<I>1. Baseline characteristics</I>
<BR/>a. Age of the female partner.<BR/>b. Primary or secondary infertility.<BR/>c. Duration of subfertility.<BR/>d. Previous fertility treatment.<BR/>
<BR/>
<I>2. Interventions used</I>
<BR/>a. Tubal surgery.<BR/>b. Expectant management.<BR/>c. IVF.<BR/>
<BR/>
<I>
<B>Outcomes</B>
</I>
<BR/>
<I>1. Primary</I>
</P>
<P>Cumulative livebirth rate per couple.</P>
<P>
<I>2. Secondary </I>
</P>
<P>a. Cumulative pregnancy rate per patient/couple.</P>
<P>b. Pregnancy rate per patient/ couple.</P>
<P>c. Livebirth rate per treatment cycle commenced.</P>
<P>d. Ectopic pregnancy rate per patient.</P>
<P>e. Multiple pregnancy rate per patient.</P>
<P>f. Incidence of OHSS per patient.</P>
<P>All assessments of trial quality and data extraction will be independently performed by three review authors (SJ, VA, BM) using forms designed according to Cochrane guidelines. Any discrepancies will be resolved by a senior review author (BM). Additional information on trial methodology or actual original trial data will be sought from the corresponding authors of trials which appear to meet the eligibility criteria but are unclear in aspects of methodology, or where the data are in a form unsuitable for meta-analysis.<BR/>
<I>
<B>Analysis</B>
</I>
</P>
<P>Should suitable trials become available in future, statistical analysis will be performed in accordance with the guidelines developed by the Gynaecology and Fertility group. Heterogeneity between the results of different studies will be examined by inspecting the scatter in the data points and the overlap in their confidence intervals and, more formally, using I<SUP>2</SUP> tests. The possible contribution of differences in trial design to any heterogeneity identified in this manner, will be investigated. Where possible, the outcomes will be pooled statistically.<BR/>
<BR/>For cross-over trials, only the data from the first phase (i.e. before cross-over) will be used.<BR/>
<BR/>For dichotomous data (e.g. pregnancy rate), results for each study will be expressed as an odds ratio with 95% confidence interval and combined for meta-analysis where appropriate, with RevMan software using the Peto-modified Mantel-Haenzel method. If possible, a sub-group analysis will be performed to assess the clinical effectiveness of tubal surgery in women with grades I, II and III tubal damage separately. Sensitivity analysis will be undertaken to examine the stability of the results in relation to a number of factors including study quality and the source of the data.</P>
<P>
<I>
<B>Time line</B>
</I>
</P>
<P>The review is expected to be updated within two years of publication on the Cochrane Library or earlier should a seminal piece of research become available. New searches for RCTs will be performed every two years thereafter, and the review updated accordingly.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 study included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 study included in qualitative synthesis&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 full-text article assessed for eligibility&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;2108 records screened&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;2108 records after duplicates removed&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;2768 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;27 additional records identified through other sources&lt;/p&gt;&lt;p&gt;(handsearch of conference abstracts and reference lists of reviews, see &lt;a link_type=&quot;APPENDIX&quot; href=&quot;01&quot; protected=&quot;true&quot;&gt;Appendix 1&lt;/a&gt;6 and &lt;a link_type=&quot;APPENDIX&quot; href=&quot;01&quot; protected=&quot;true&quot;&gt;Appendix 1&lt;/a&gt;7)&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2107 records excluded&lt;/p&gt;&lt;p&gt;2106 not RCT&lt;/p&gt;&lt;p&gt;1 not comparing tubal surgery with IVF/expectant management&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 study excluded as it did not meet inclusion criteria&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>